<SEC-DOCUMENT>0001185185-25-000890.txt : 20250804
<SEC-HEADER>0001185185-25-000890.hdr.sgml : 20250804
<ACCEPTANCE-DATETIME>20250804060222
ACCESSION NUMBER:		0001185185-25-000890
CONFORMED SUBMISSION TYPE:	PRE 14A
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20251010
FILED AS OF DATE:		20250804
DATE AS OF CHANGE:		20250804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IGC Pharma, Inc.
		CENTRAL INDEX KEY:			0001326205
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				202760393
		STATE OF INCORPORATION:			MD
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		PRE 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32830
		FILM NUMBER:		251177869

	BUSINESS ADDRESS:	
		STREET 1:		10224 FALLS ROAD
		CITY:			POTOMAC
		STATE:			MD
		ZIP:			20854
		BUSINESS PHONE:		301-983-0998

	MAIL ADDRESS:	
		STREET 1:		10224 FALLS ROAD
		CITY:			POTOMAC
		STATE:			MD
		ZIP:			20854

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	India Globalization Capital, Inc.
		DATE OF NAME CHANGE:	20050505
</SEC-HEADER>
<DOCUMENT>
<TYPE>PRE 14A
<SEQUENCE>1
<FILENAME>igcpre14a080225.htm
<DESCRIPTION>FORM PRE 14A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Sat Aug 02 17:02:56 UTC 2025 -->
<html xmlns:compsci="http://compsciresources.com" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:igc="http://www.indiaglobalcap.com/20250805" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://xbrl.us/us-types/2009-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 16pt"><b>UNITED
STATES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 16pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Washington,
D.C. 20549</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 10%"><div style="font-size: 1pt; border-top: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 16pt"><b><span style="-sec-ix-hidden: hidden-fact-0">SCHEDULE
14A</span></b></span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 10%"><div style="font-size: 1pt; border-top: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Proxy
Statement Pursuant to Section 14(a) of the</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
Exchange Act of 1934</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
by the Registrant &#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
by a Party other than the Registrant &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preliminary
Proxy Statement</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Confidential,
for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</b></span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">&#9744;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive
Proxy Statement</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive
Additional Materials</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
Material Pursuant to &#167;240.14a-12</span></td>
</tr></table><div>
</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-139"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span style="text-decoration:underline">IGC
Pharma, Inc.</span></b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">&#160;
&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;
&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;
&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
of Person(s) Filing Proxy Statement, if other than the Registrant)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
of Filing Fee (Check all boxes that apply):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
fee required.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee
computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee
paid previously with preliminary materials.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee
computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.</span></td>
</tr></table><div>


</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IGC
Pharma, Inc.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10224
Falls Road, Potomac, </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maryland,
20854</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANNUAL
MEETING OF STOCKHOLDERS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Stockholder:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
are cordially invited to attend the 2025 Annual Stockholders&#8217; Meeting of IGC Pharma, Inc. (&#8220;IGC,&#8221; &#8220;we,&#8221;
&#8220;us,&#8221; &#8220;our,&#8221; or the &#8220;Company&#8221;), which is to be held at 10224 Falls Road, Potomac, Maryland, 20854,
on October 10, 2025, at 11:00 a.m. local time. We reserve the right to take any additional precautionary measures we deem appropriate
in relation to the physical meeting and access to our premises. We may need to change the time, date, or location of the Annual Meeting.
If we do so, we will announce any changes in advance as required by the Securities and Exchange Commission (the &#8220;SEC&#8221;), and
by any applicable state law. The Annual Meeting will commence with a discussion and voting on the matters set forth in the accompanying
Notice of Annual Meeting of Stockholders, followed by a report on our operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notice of Annual Meeting of Stockholders and Proxy Statement, which more fully describes the formal business to be conducted at the Annual
Meeting, follows this letter. A copy of our Annual Report to Stockholders for the fiscal year ended March 31, 2025, is also enclosed.
We encourage you to carefully read these materials. The notice and the accompanying proxy statement will be mailed to all stockholders
by August 25, 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
or not you plan to attend the Annual Meeting, it is important that your shares be represented and voted at the Annual Meeting. Therefore,
I urge you to promptly vote and submit your proxy by signing, dating, and returning your proxy card. Beneficial owners of shares held
in street name should follow the instructions in the Proxy Statement for voting their shares. If you are a record holder and you decide
to attend the Annual Meeting, you will be able to vote in person, even if you have previously submitted your proxy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPORTANT
NOTICE REGARDING THE INTERNET AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON OCTOBER 10, 2025:</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>This
Proxy Statement, the Notice of Annual Meeting of Stockholders, and our Annual Report to Stockholders are available at http://www.igcpharma.com.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Except
as otherwise stated, information on our website is not a part of this Proxy Statement.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
will send a full set of proxy materials or a Notice of Internet Availability of Proxy Materials (the </b>&#8220;<b>Notice of Internet
Availability</b>&#8221;<b>) on or about August 25, 2025, and provide access to our proxy materials over the Internet, beginning on for
the holders of record and beneficial owners of our shares of common stock as of the close of business on the record date. The Notice
of Internet Availability instructs you on how to access and review this Proxy Statement and our fiscal 2025 Annual Report to Stockholders.
The Notice of Internet Availability also instructs you on how you may authorize a proxy to vote your shares over the Internet and provides
instructions on how you can request a paper copy of these documents if you desire, and how you can enroll in e-delivery. If you received
your annual meeting materials via email, the email contains voting instructions and links to our annual report and proxy statement on
the internet.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
behalf of the Board of Directors, thank you for your continued support.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 50%; text-align: justify"><span style="font-size: 10pt"><b>Sincerely,</b></span></td>
    <td style="width: 50%; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 10pt"><b>/s/ Richard Prins</b></span></td>
    <td style="padding-bottom: 1pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Chairman</b></span></td>
    <td style="text-align: justify">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; vertical-align: bottom; width: 0.4in"><img alt="" src="image_002.jpg"/></td><td style="text-align: left; vertical-align: bottom; width: 3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;|&#160;FYE2025 Form PRE 14A</span></td><td style="text-align: right; vertical-align: bottom"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IGC
Pharma, Inc.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10224
Falls Road, Potomac, </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maryland,
20854</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PRELIMINARY
PROXY STATEMENT&#8212;SUBJECT TO COMPLETION</b></span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTICE
OF ANNUAL MEETING OF STOCKHOLDERS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Annual Meeting of Stockholders (the &#8220;Annual Meeting&#8221;) for the year ended March 31, 2025, of IGC Pharma, Inc. (&#8220;IGC,&#8221;
&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; or the &#8220;Company&#8221;) will be held at 10224 Falls Road, Potomac, Maryland,
20854, on October 10, 2025, at 11:00 a.m. local time. Voting materials, which include this Proxy Statement, the proxy card, and our Annual
Report for the fiscal year ended March 31, 2025 (&#8220;Fiscal 2025&#8221;), are first being mailed to Stockholders of the Company on
or about August 25, 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
who desire to attend the Annual Meeting should indicate such planned attendance by marking the appropriate box on the enclosed proxy
card. Stockholders who do not indicate attendance at the Annual Meeting by proxy will be required to present acceptable proof of stock
ownership to attend the Annual Meeting. All stockholders must furnish personal photo identification for admission to the Annual Meeting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will hold the Annual Meeting for the following purposes:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
elect Mr. Ram Mukunda and Mr. James Moran to the Company&#8217;s Board of Directors to serve as Class C directors until the 2028 Annual
Meeting of Stockholders and until such director&#8217;s respective successor shall be duly elected and qualified, or until such director&#8217;s
earlier death, resignation, or removal from office;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
ratify the appointment of Manohar Chowdhry &amp; Associates as the Company&#8217;s independent registered public accounting firm for
the 2026 fiscal year;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
approve the grant of 5,000,000 shares of common stock, governed by the 2018 Omnibus Incentive Plan, to be granted from time to time to
the Company&#8217;s current and new employees, advisors, directors, and consultants by the Board of Directors, pursuant to certain metrics
including performance, vesting, and incentive as set by the Board of Directors and or the CEO;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
effect an amendment to our Amended and Restated Articles of Incorporation to increase the authorized number of shares of our common stock
from 150,000,000 shares to 600,000,000 shares of common stock;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
act upon such other matters as may properly come before the Annual Meeting, including any proposal to adjourn or postpone the Annual
Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies (the &#8220;Adjournment Proposal&#8221;).</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
attention is directed to the Proxy Statement accompanying this Notice for a more complete description of each of the foregoing items
of business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Only
holders of record of our common stock at the close of business on July 28, 2025, are entitled to notice of and to vote at the Annual
Meeting and at any and all adjournments or postponements thereof.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 40%; text-align: justify"><span style="font-size: 10pt"><b>By Order of the Board of Directors,</b></span></td>
    <td style="width: 60%; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 10pt"><b>Richard Prins</b></span></td>
    <td style="padding-bottom: 1pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Chairman</b></span></td>
    <td style="text-align: justify">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 3; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; vertical-align: bottom; width: 0.4in"><img alt="" src="image_002.jpg"/></td><td style="text-align: left; vertical-align: bottom; width: 3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;|&#160;FYE2025 Form PRE 14A</span></td><td style="text-align: right; vertical-align: bottom"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IGC
PHARMA, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROXY
STATEMENT</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors of the Company (the &#8220;Board of Directors&#8221; or the &#8220;Board&#8221;) is soliciting proxies for the Annual
Meeting. You may revoke your proxy at any time prior to voting at the Annual Meeting by submitting a later dated proxy or by giving timely
written notice of your revocation to the Secretary of the Company. Proxies properly executed and received by the Secretary prior to the
Annual Meeting, and not revoked, will be voted in accordance with the terms of the proxies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registered
stockholders holding shares of the Company&#8217;s common stock may vote by completing, signing, dating the proxy card, and returning
it as promptly as possible. The Company will pay all of the costs associated with this proxy solicitation. Proxies may be solicited in
person or by mail, telephone, telefacsimile, or other means of electronic transmission by our directors, officers, and employees. We
will also reimburse banks, brokerage firms, and other custodians, nominees, and fiduciaries for their reasonable expenses in forwarding
soliciting materials to the beneficial owners of the Company&#8217;s common stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you desire to attend the Annual Meeting, you should indicate your intent to attend in person when voting by marking the appropriate box
on the enclosed proxy card. If you do not indicate attendance at the Annual Meeting on the proxy, you will be required to present acceptable
proof of stock ownership to attend. All stockholders who attend the Annual Meeting must furnish personal photo identification for admission.
If your shares are not registered in your own name, and you plan to attend the Annual Meeting and vote your shares in person, you should
contact your broker or agent in whose name your shares are registered to obtain a proxy executed in your favor and bring it to the Annual
Meeting in order to vote.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VOTING
RIGHTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
stockholders are entitled to one vote at the Annual Meeting for each share of Company&#8217;s common stock held of record as of July
28, 2025 (the &#8220;Record Date&#8221;). As of the close of business on the record date, there were 90,809,112 shares of common stock
outstanding. A majority of the shares entitled to vote, present in person or represented by proxy, will constitute a quorum at the Annual
Meeting. If your shares are held in &#8220;street name,&#8221; these proxy materials are being forwarded to you by your bank or brokerage
firm (the &#8220;Record Holder&#8221;), along with a voting instruction card. As the beneficial owner, you have the right to direct the
Record Holder on how to vote your shares, and the Record Holder is required to vote your shares in accordance with your instructions.
If you do not give instructions to your bank or brokerage firm, it will nevertheless be entitled to vote your shares in its discretion
on &#8220;routine matters.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VOTES
REQUIRED</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of (i) the election of the nominee for director (Proposal 1); (ii) the ratification of the appointment of Manohar Chowdhry &amp; Associates
as the Company&#8217;s independent registered public accountants (Proposal 2); (iii) the approval of the grant of Compensation Shares
(Proposal 3) requires a majority of the votes present at the Annual Meeting and entitled to vote, in person or by proxy; and (iv) the
approval to amend our Amended and Restated Articles of Incorporation to increase the authorized number of shares of our common stock
from 150,000,000 shares to 600,000,000 shares of common stock (Proposal 4) requires an affirmative vote of two-thirds of the votes present
at the Annual Meeting and entitled to vote, in person or proxy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BROKER
NON-VOTES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
&#8220;broker non-vote&#8221; occurs when a broker submits a proxy card with respect to shares held in a fiduciary capacity (typically
referred to as being held in &#8220;street name&#8221;) but declines to vote on a particular matter because the broker has not received
voting instructions from the beneficial owner. Under the rules that govern, brokers who are voting with respect to shares held in street
name have the discretion to vote such shares on routine matters but not on non-routine matters.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
election of directors in an uncontested election is deemed to be a non-routine matter. The vote to approve grant of shares of common
stock from time to time to the Company&#8217;s current and new employees, advisors, directors, and consultants by the Board of Directors
are also deemed to be a non-routine matter. Accordingly, if you hold your shares in street name, in order for your shares to be voted
for the election of directors at the Annual Meeting (Proposal One), the grant of up to 5,000,000 shares of common stock, governed by
the 2018 Omnibus Incentive Plan, to the Company&#8217;s current and new employees, advisors, directors, and consultants by the Board
of Directors (Proposal Three) you must provide voting instructions to your broker in accordance with the voting instruction card that
you will receive from your broker. Proxies received but marked as abstentions or treated as broker non-votes will be included in the
calculation of the number of shares considered to be present at the Annual Meeting for quorum purposes. In determining whether the proposal
has been approved, abstentions will be counted for purposes of determining the presence or absence of a quorum and will be counted as
votes against the purpose, and broker non-votes will not be counted as votes for or against the proposal or as votes present and voting
on the proposal.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 4; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; vertical-align: bottom; width: 0.4in"><img alt="" src="image_002.jpg"/></td><td style="text-align: left; vertical-align: bottom; width: 3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;|&#160;FYE2025 Form PRE 14A</span></td><td style="text-align: right; vertical-align: bottom"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purposes of this Annual Meeting, the Company has determined that the re-appointment of its independent auditors (Proposal Two) is
a routine matter under applicable rules. Likewise, the authorization to increase the Company&#8217;s authorized shares (Proposal Four)
is deemed to be a routine matter. A broker or other nominees may generally vote on routine matters, and therefore, no broker non-votes
are expected to exist in connection with Proposal Two and Proposal Four. The approval of the Adjournment Proposal (Proposal Five) requires
a majority of all the votes cast at a meeting at which a quorum is present. Approval of the Adjournment Proposal is not conditioned upon
the approval of any other proposals in this proxy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not aware of any matters that are to come before the Annual Meeting other than those described in this Proxy Statement; however,
if other matters do properly come before the Annual Meeting, it is the intention of the persons named in the proxy card to vote for such
proxy in accordance with their best judgment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SOLICITATION
OF PROXIES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will bear the cost of soliciting proxies. In addition to soliciting stockholders by mail through our employees, we will request banks,
brokers, and other custodians, nominees, and fiduciaries to solicit customers for whom they hold our stock and will reimburse them for
their reasonable, out-of-pocket costs. We may use the services of our officers, directors, and others to solicit proxies, personally
or by telephone, without additional compensation. We have also engaged InvestorCom to solicit proxies on our behalf. We anticipate that
the fees to InvestorCom will be approximately $4,000.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROPOSAL
ONE</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ELECTION
OF DIRECTORS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors is currently divided into three classes, Class A, Class B, and Class C, with only one class of directors being elected
in each year and each class serving a three-year term. At the 2025 Annual Meeting, Mr. Ram Mukunda and Mr. James Moran, Class C directors,
are to be elected as members of our Board of Directors to serve until the 2028 Annual Stockholders Meetings, respectively, and until
their successors are duly elected and qualified, or until their earlier resignation, removal, or death. Our Board of Directors has nominated
both Mr. Ram Mukunda and Mr. James Moran to serve as Class C directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
other current directors consist of one Class B director and two Class A directors, who will serve until the 2026 and 2027 Annual Stockholders&#8217;
Meetings, respectively, and until their successors are duly elected and qualified.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should
any vacancy occur on the Board of Directors, the remaining directors would be able to fill such vacancy by the affirmative vote of a
majority of the remaining directors in office, even if the remaining directors do not constitute a quorum. Any director elected by the
Board of Directors to fill a vacancy would hold office for the remainder of the full term of the class of directors in which the vacancy
occurred and until a successor is elected and qualified. If the size of the Board is increased, additional directors will be apportioned
among the three classes in order to make all classes as nearly equal as possible.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below is information regarding our Class C director nominees. Except as set forth below, there are no family relationships between
any of our directors or executive officers. Each director holds office until he or she resigns or is removed and his or her successor
is elected and qualified.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.25pt 0.4pt; vertical-align: bottom; width: 25%; border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.25pt 0.4pt; vertical-align: bottom; width: 6%; border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.25pt 0.4pt; vertical-align: bottom; width: 6%; border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.25pt 0.4pt; vertical-align: bottom; width: 40%; border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.25pt 0.4pt; vertical-align: bottom; width: 9%; border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
    Since</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.25pt 0.4pt; vertical-align: bottom; width: 9%; border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Term
    will Expire</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James Moran</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ram Mukunda</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, Chief Executive
    Officer, and Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2005</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2028</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>James
Moran (Congressman Moran)</b> has served on the Board as an Independent Director since January 2022. He served on Virginia&#8217;s 8th
Congressional District for 24 years, where he was known as a &#8220;Problem Solver.&#8221; Throughout his tenure, he demonstrated bipartisan
leadership and worked across the aisle to find common ground to resolve complex issues. He served on the Appropriation, Banking and Finance,
and Budget committees. He played a leadership role in the areas of defense, health, and the environment. During his 24 years in Congress,
Congressman Moran was recognized as a champion of innovative research and development in areas including healthcare and national security,
environmental protection and sustainability, and international trade and fiscal responsibility. He rose to senior leadership on the Appropriations
Committee, enabling him to bring billions of dollars into his Northern Virginia communities of Alexandria, Arlington, and Fairfax County.
Having retired after 35 years in elected office, Congressman Moran is now with a major law firm and represents international and domestic
clients in the defense, technology, entertainment, and international diplomacy sectors. He also serves in leadership roles for several
non-profit foundations and is also a member of the Government Blockchain Association. Congressman Moran received a Master&#8217;s Degree
in Public Administration from the University of Pittsburgh Graduate School of Public and International Affairs and a Bachelor&#8217;s
in Economics from the College of the Holy Cross.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 5; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; vertical-align: bottom; width: 0.4in"><img alt="" src="image_002.jpg"/></td><td style="text-align: left; vertical-align: bottom; width: 3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;|&#160;FYE2025 Form PRE 14A</span></td><td style="text-align: right; vertical-align: bottom"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Congressman
Moran introduced the AUTISM Educators Act in 2012, which funded partnerships between public schools and higher education and non-profit
organizations to promote teaching skills for educators working with high functioning autism students. He understands that treatment and
education for conditions such as Autism and Alzheimer&#8217;s disease have the potential to positively impact millions of lives. With
his extensive experience in Congress and as a policy advisor on topics including health, technology, and education, we are confident
Congressman Moran will be a great asset to IGC, especially at a time when we pursue Phase 2/3 human trials on IGC- AD1 on individuals
that have Alzheimer&#8217;s disease. Congressman Moran&#8217;s extensive experience makes him qualified to serve as a director of our
Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 27, 2022, the Board of Directors appointed Mr. James Moran as a member of both the Company&#8217;s Audit and Compensation Committee,
effective immediately.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ram
Mukunda</b> has served as Founder, Director, CEO, and President since inception. He is responsible for general management and, over the
past 11 years, has been largely responsible for the Company&#8217;s strategy and positioning in the pharmaceutical industry. He has been
the chief inventor and architect of most of the Company&#8217;s patent filings and the thrust into R&amp;D and medical trials, which
support the Company&#8217;s desire to bring low-cost medications that address diseases and ailments that affect humankind. Prior to IGC,
from January 1990 to May 2004, Mr. Mukunda served as Founder and CEO of Startec Global Communications, which he took public in 1997 on
NASDAQ. Prior to Startec, he served as a Strategic Planning Advisor at Intelsat, a communications satellite services provider, and prior
to that, worked in the bond market for a boutique firm on Wall Street. Mr. Mukunda serves as an Emeritus member on the Board of Visitors
at the University of Maryland, School of Engineering. From 2001 to 2003, he was a Council Member at Harvard&#8217;s Kennedy School of
Government, Belfer Center of Science and International Affairs. Mr. Mukunda is the recipient of several awards, including, among others,
the 2013 University of Maryland&#8217;s International Alumnus of the Year Award, the 2001 Distinguished Engineering Alumnus Award, and
the 1998 Ernst &amp; Young, LLP&#8217;s Entrepreneur of the Year Award. He holds a B.S. degree in Electrical Engineering, a B.S. degree
in Mathematics, and a M.S. in Engineering from the University of Maryland. Mr. Mukunda has traveled extensively and managed companies
in Europe and Asia. He has over 25 years of experience managing public companies and has acquired and integrated over 20 companies. His
in-depth business experience in the pharmaceutical and OTC industries, his knowledge of U.S. capital markets, capital structuring, international
joint ventures, and broad science and engineering background make him qualified to serve as a director of our Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following sets forth information regarding our current Class A and Class B directors. Except as set forth below, there are no family
relationships between any of our directors or executive officers. Each director holds office until he or she resigns or is removed and
his or her successor is duly elected and qualified.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.25pt 0.4pt; vertical-align: bottom; width: 25%; border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.25pt 0.4pt; vertical-align: bottom; width: 6%; border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.25pt 0.4pt; vertical-align: bottom; width: 6%; border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.25pt 0.4pt; vertical-align: bottom; width: 40%; border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.25pt 0.4pt; vertical-align: bottom; width: 9%; border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director<br/>

    Since</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.25pt 0.4pt; vertical-align: bottom; width: 9%; border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Term
    will <br/>
Expire</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard Prins</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board of Directors</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2007</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2027</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terry Lierman</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2027</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Claudia Grimaldi</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice President, Principal Financial
    Officer, Chief Compliance Officer, and Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Richard
Prins</b> has been our Chairman, Audit Committee, and Compensation Committee Chairman since 2012 and has served as an Independent Director
since May 2007. Mr. Prins has extensive experience in private equity investing and investment banking. From March 1996 to 2008, he was
the Director of Investment Banking at Ferris, Baker Watts, Incorporated (&#8220;FBW&#8221;). Mr. Prins served in a consulting role for
RBC until January 2009. Since February 2003, he has been on the board of Amphastar Pharmaceuticals, Inc. Mr. Prins holds a B.A. degree
from Colgate University and an M.B.A. from Oral Roberts University. Mr. Prins has substantial knowledge and experience with U.S. capital
markets, has served on and chaired audit and compensation committees of boards, and has extensive experience in finance, accounting,
and internal controls over financial reporting. His knowledge of the pharmaceutical industry and experience with U.S. capital markets
make him qualified to serve as a director of our Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Terry
L. Lierman</b> has served on the Board as an Independent Director since March 2024. Mr. Lierman is currently Co-Chair of the Board of
Advisors at the Institute of Human Virology (&#8220;IHV&#8221;), a center in the U.S. focused on accelerating the discovery of diagnostics
and therapeutics for deadly viral and immune disorders, and a member of the Board of Visitors at the La Follette School of Public Affairs
at the University of Wisconsin, his alma mater. Mr. Lierman founded the Children&#8217;s Research Institute, one of America&#8217;s top
children&#8217;s research programs, the Pancreatic Cancer Action Network (&#8220;PanCAN&#8221;), and the National Organization on Fetal
Alcohol Syndrome (&#8220;NOFAS&#8221;). In addition, from 1987 to 1999, he served as a director/trustee of the NY Life-Mainstay Funds.
His distinguished career includes serving at the National Institutes of Health (&#8220;NIH&#8221;), as the chief administrator for drug
research and development at the National Cancer Institute (&#8220;NCI&#8221;), and as the Staff Director for the Committee on Appropriations
at the U.S. Senate and the Chief of Staff and White House liaison to the U.S. House of Representative&#8217;s Majority Leader. Mr. Lierman&#8217;s
vast healthcare expertise will undoubtedly play a pivotal role in driving our mission to develop innovative therapeutics for crucial
unmet needs. His extensive experience uniquely qualifies him to serve as a director of our company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; vertical-align: bottom; width: 0.4in"><img alt="" src="image_002.jpg"/></td><td style="text-align: left; vertical-align: bottom; width: 3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;|&#160;FYE2025 Form PRE 14A</span></td><td style="text-align: right; vertical-align: bottom"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Claudia
Grimaldi</b>, has served on the Board of Directors since August 18, 2023 and is the Vice-president, PFO, Chief Compliance Officer, and
Director, is responsible for managing the accounting and finance teams in various countries and is responsible for ensuring timely and
accurate statutory and regulatory compliance (SEC, FINRA, NYSE, IRS, XETRA 2, among others). In addition, she is responsible for building
and managing an international team of doctors, scientists, and advisors that conduct and manage pre-clinical and FDA registered trials
focused on Alzheimer&#8217;s disease. She is also responsible for relationships with partners that provide, among others, animal studies,
cannabinoids, and software for AI. She has more than thirteen (13) years of experience with Securities and Exchange Commission (&#8220;SEC&#8221;)
filings, regulatory compliance, and disclosures, having held increasing responsibilities first as Manager of financial reporting and
compliance from May 2011 to 2013 and then as General Manager of financial reporting and compliance from 2013 to May 2018. She also serves
as a Director/Manager for some of our subsidiaries. Ms. Grimaldi graduated summa cum laude from Javeriana University, a top five university
in Colombia, with a Bachelor of Arts in Psychology. She holds an MBA in General Management, graduating with Highest Honors, from Meredith
College, in North Carolina. She is a member of Delta Mu Delta International Honor Society. She has also completed Executive Education
courses on SEC compliance, finance from UVA, and corporate governance from the Columbia Business School. In addition, she has attended
the Darden School of Business Financial Management Executives program at the University of Virginia, and SEC reporting and compliance
seminars. She also completed her certification program of the National Association of Corporate Directors . She is also fluent in both
English and Spanish.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms.
Grimaldi brings a wealth of experience and qualifications that make her an excellent fit for the board. Ms. Grimaldi&#8217;s experience
with SEC filing procedures is invaluable in ensuring regulatory compliance and transparency within our public company. Additionally,
her in-depth understanding of Colombia, and South America where our company has invested in human capital, provides valuable insights
into the market dynamics, cultural nuances, and business opportunities within the region. Her SEC filing experience, understanding of
Colombia, qualifications in business administration, and general business acumen make her qualified to serve as a director of our Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
officers are appointed by our Board of Directors. Each executive officer holds his or her office until he or she resigns or is removed
by the Board or his or her successor is elected and qualified. All directors hold office until the annual meeting of the stockholders
in the year set forth above in the table and until their successors have been duly elected or qualified. There are no family relationships
between any of our executive officers or directors. There are currently no legal proceedings against the Company&#8217;s directors or
officers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Vote
Required and Board of Directors Recommendation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
election of the nominee for director requires a majority of the votes present at the meeting and entitled to vote, in person or by proxy.
In determining whether the proposal has been approved, abstentions will be counted for the proposal of determining the presence or absence
of a quorum and will be counted as votes against the proposal, and broker non-votes will not be counted as votes for or against the proposal
or as votes present and voting on the proposal.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
do not have the right to cumulate their votes in the election of directors. If, at the time of the Annual Meeting, the nominee should
be unavailable to serve as a director, it is intended that votes will be cast, in accordance with the enclosed proxy, for such substitute
nominee as may be nominated by the Board of Directors, or the Board of Directors may reduce the number of directors. The nominee has
consented to being named in this Proxy Statement and to serve if elected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Board of Directors recommends that the stockholders vote FOR the election of the nominees set forth above. Properly executed and delivered
proxies solicited by management for which no specific direction is included will be voted FOR the election of the nominees listed to
serve as directors.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 7; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; vertical-align: bottom; width: 0.4in"><img alt="" src="image_002.jpg"/></td><td style="text-align: left; vertical-align: bottom; width: 3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;|&#160;FYE2025 Form PRE 14A</span></td><td style="text-align: right; vertical-align: bottom"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROPOSAL
TWO</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RATIFICATION
OF THE APPOINTMENT OF</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEPENDENT
REGISTERED PUBLIC ACCOUNTANTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 26, 2025, the Audit Committee of the Board selected Manohar Chowdhry &amp; Associates as the Company&#8217;s independent registered
public accountants for fiscal year ending March 31, 2026.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manohar
Chowdhry &amp; Associates served as the Company&#8217;s independent auditors for the fiscal years ended March 31, 2018, through March
31, 2025, reviewing the Company&#8217;s financial statements. Services provided to the Company by Manohar Chowdhry &amp; Associates for
the 2024 and 2025 fiscal years are described in &#8220;Audit Information.&#8221; A representative of Manohar Chowdhry &amp; Associates
will not be present at the meeting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
stockholder ratification is not required by the Company&#8217;s Bylaws or otherwise, the Board of Directors is requesting that stockholders
ratify the selection of Manohar Chowdhry &amp; Associates as the Company&#8217;s independent registered public accountants to make an
examination of the financial statements of the Company for the 2026 fiscal year. If stockholders do not ratify the selection of Manohar
Chowdhry &amp; Associates at the Annual Meeting, the Audit Committee will reconsider whether to retain that firm for future audits. Even
if the selection is ratified, the Audit Committee in its discretion may direct the appointment of different independent auditors at any
time during the year if it determines that such change would be in the best interests of the Company and its stockholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Vote
Required and Board of Directors Recommendation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ratification of the appointment of Manohar Chowdhry &amp; Associates as the Company&#8217;s independent registered public accountants
for the 2026 fiscal year will require the affirmative vote of the holders of a majority of the shares of outstanding common stock present
or represented at the Annual Meeting and entitled to vote thereat. In determining whether the proposal has been approved, abstentions
will be counted as votes against the proposal, and broker non-votes (if any) will not be counted as votes for or against the proposal
or as votes present and voting on the proposal.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Board of Directors recommends that you vote FOR the ratification of the appointment of Manohar Chowdhry &amp; Associates as the Company</b>&#8217;<b>s
independent registered public accountants for the 2026 fiscal year. Proxies solicited by management for which no specific direction is
included will be voted FOR ratification of the appointment of Manohar Chowdhry &amp; Associates.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; vertical-align: bottom; width: 0.4in"><img alt="" src="image_002.jpg"/></td><td style="text-align: left; vertical-align: bottom; width: 3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;|&#160;FYE2025 Form PRE 14A</span></td><td style="text-align: right; vertical-align: bottom"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROPOSAL
THREE</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GRANT
OF 5,000,000 SHARES OF COMMON STOCK</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TO
OUR CURRENT AND NEW OFFICERS, DIRECTORS, EMPLOYEES,</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ADVISORS
AND CONSULTANTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors is requesting that IGC stockholders approve a grant of 5,000,000 shares of common stock, governed by the 2018 Omnibus
Incentive Plan, to current and new officers, directors, employees, advisors, and consultants (the &#8220;Compensation Shares&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee believes that the grant of the Compensation Shares to some of its current officers, employees, directors, advisors,
and consultants is important in order to align their interests with the interests of the Company and its shareholders, as well as to
retain them as the Company builds its business in the pharmaceuticals industry brimming with opportunity, high growth, and high relative
valuations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Among
the accomplishments achieved by the Company in Fiscal 2025 are the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Positive
Interim Data Reinforces IGC-AD1&#8217;s Potential:</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
                                            2, 2024: IGC Pharma released positive interim data from its ongoing multicenter, randomized,
                                            double-blind, placebo-controlled Phase 2, officially named &#8220;CALMA&#8221; (Calming Agitation
                                            in Alzheimer&#8217;s) trial for agitation in Alzheimer&#8217;s disease, providing early validation
                                            of IGC-AD1&#8217;s therapeutic promise. The interim data demonstrated a clinical and statistically
                                            significant reduction in agitation in patients with Alzheimer&#8217;s compared to placebo
                                            at week 6, with clinical improvements observed as early as week 2. Agitation affects approximately
                                            76% of the estimated 50 million individuals living with Alzheimer&#8217;s worldwide, yet
                                            only one treatment is currently FDA-approved&#8212;highlighting a vast unmet medical need
                                            and multi-billion-dollar opportunity.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
                                            14, 2024: Further interim data from the CALMA trial highlighted additional cognitive benefits
                                            of IGC-AD1 in Alzheimer&#8217;s patients, Notably, results showed a reduction in sleep disturbances
                                            by approximately 71% at week 2 and 78% at week 6 for those on active medication, suggesting
                                            a broader impact beyond agitation. These results underscore the potential of IGC-AD1 as a
                                            multifaceted treatment for Alzheimer&#8217;s symptoms.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Broadening
IGC-AD1&#8217;s Therapeutic Scope: Targeting Underlining Alzheimer&#8217;s Pathology:</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
                                            2, 2024: The Company announced an expansion of its clinical research program for IGC-AD1,
                                            moving beyond agitation to directly target cognitive impairment and the fundamental pathology
                                            of Alzheimer&#8217;s disease. This strategic expansion includes efforts to evaluate IGC-AD1&#8217;s
                                            potential to reduce amyloid plaques, neurofibrillary tangles, and improve mitochondrial functioning,
                                            hallmarks of the disease. This broadens IGC-AD1&#8217;s potential as a disease-modifying
                                            therapy and expands its addressable market, representing a major step forward in our mission
                                            to combat Alzheimer&#8217;s.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Strategic
Expansion of Clinical Research Program to Accelerate Enrollment and Broaden Patient Access:</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Throughout
                                            Fiscal Year 2025, IGC Pharma expanded its network of clinical trial sites for the CALMA trial,
                                            adding multiple strategic locations across North America. These expansions included leading
                                            research institutions and sites in diverse geographic areas such as Ontario (Canada), Florida,
                                            Rhode Island, Puerto Rico, and Oklahoma. This strategic broadening of our clinical trial
                                            footprint is designed to accelerate patient enrollment, enhance access to diverse patient
                                            populations, and strengthen the overall robustness of our study.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Innovation
in Artificial Intelligence and Recognitions:</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
                                            4, 2025: The Company advanced development on its Multimodal Interpretable Transformer for
                                            Alzheimer&#8217;s disease (&#8220;MINT&#8221;-AD), its proprietary AI-based diagnostic tool
                                            designed to aid in the early detection of Alzheimer&#8217;s disease and related dementias.
                                            The system integrates multimodal data to support earlier intervention, physician decision-making,
                                            and personalized risk stratification-addressing a critical unmet need in the Alzheimer&#8217;s
                                            diagnostic pathway.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
                                            1, 2024: IGC Pharma celebrated winning two awards in the prestigious PREPARE Challenge (Pioneering
                                            Research for Early Prediction of Alzheimer&#8217;s and Related Dementias EUREKA Challenge),
                                            showcasing our innovative research capabilities and thought leadership in the field.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors will determine, subject to vesting, the award of the Compensation Shares among its current officers, employees, directors,
advisors, and consultants based on the Compensation Committee&#8217;s recommendation and depending on specific factors like individual&#8217;s
contribution to the Company&#8217;s business advancement and creation of intellectual property, NYSE/SEC/IRS compliance, business strategy,
overhead and expenses control/savings and management of daily operations, amongst others. As of the date of this Proxy Statement, IGC
has no undisclosed contractual agreement to issue to any of its current officers, employees, directors, advisors, and consultants any
shares of the issued and outstanding shares of the common stock of IGC. As of the date of this Proxy Statement, the Compensation Committee
has not made a determination of the amount of Compensation Shares to be awarded to current officers, employees, directors, advisors,
and consultants and the amount to be used in the future to recruit specialists. The NYSE American rules require IGC stockholders&#8217;
approval prior to the issuance of the Compensation Shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the Record Date, there were approximately 3.8 million shares of the Company&#8217;s Common Stock available for future grants under the
Company&#8217;s existing equity plan. On the Record Date, the closing price of our Common Stock was 0.38 per share. On the Record Date,
directors and executive officers, including the Named Executive Officers, and approximately 70 employees, advisors, and consultants of
the Company were eligible to participate in the receipt of the Compensation Shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>




</div><!-- Field: Page; Sequence: 9; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; vertical-align: bottom; width: 0.4in"><img alt="" src="image_002.jpg"/></td><td style="text-align: left; vertical-align: bottom; width: 3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;|&#160;FYE2025 Form PRE 14A</span></td><td style="text-align: right; vertical-align: bottom"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
Authorized for Issuance Under Equity Compensation Plans</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows, as of March 31, 2025, information regarding outstanding awards available under our compensation plans (including
individual compensation arrangements) under which our equity securities may be delivered.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1pt solid">Plan category</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(a)<br/> Number of<br/> securities<br/>
    to be<br/> issued upon<br/> exercise of<br/> outstanding<br/> options,<br/> warrants<br/> and rights</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(b)<br/> Weighted-<br/> average
    exercise<br/> price of<br/> outstanding<br/> options,<br/> warrants <br/> and rights</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(c)<br/> Number of<br/> securities<br/> available for<br/> future<br/> issuance<br/> (excluding<br/> shares in<br/> column (a)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Equity compensation plans approved by security holders:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 0.25pt">2018 Omnibus Incentive Plan (1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,106,496</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.34</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">748,168</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Special Grant (2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,202,501</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.51</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,973,498</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
of our 2018 Omnibus Incentive Plans, as approved by our stockholders on November 8, 2017. See Note 14, &#8220;Stock-Based Compensation&#8221;
of the Notes to the Consolidated Financial Statements included in this report.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
of 2 million shares as a special grant of common stock, as approved by our stockholders on January 7, 2020, 2.5 million shares as a special
grant of common stock, as approved by our stockholders on January 11, 2021, 3.5 million shares as a special grant of common stock, as
approved by our stockholders on October 15, 2021, 3 million shares as a special grant of common stock, as approved by stockholders on
September 9, 2022, 3 million shares as special grant of common stock, as approved by stockholders on August 18, 2023 and 5 million shares
as special grant of common stock, as approved by stockholders on August 23, 2024.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Vote
Required for Special Grant of Shares</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
approval of the grant of Compensation Shares will require the affirmative vote of the holders of a majority of the shares of common stock
present or represented at the Annual Meeting and entitled to vote thereat. In determining whether the proposal has been approved, abstentions
will be counted as votes against the proposal, and broker non-votes will not be counted as votes for or against the proposal or as votes
present and voting on the proposal.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Board of Directors recommends that you vote FOR the grant of Proxies solicited by management for which no specific direction is included
and will be voted FOR the grant of the Compensation Shares.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 10; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; vertical-align: bottom; width: 0.4in"><img alt="" src="image_002.jpg"/></td><td style="text-align: left; vertical-align: bottom; width: 3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;|&#160;FYE2025 Form PRE 14A</span></td><td style="text-align: right; vertical-align: bottom"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROPOSAL
FOUR</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INCREASE
THE COMPANY&#8217;S AUTHORIZED SHARES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OF
COMMON STOCK TO 600,000,000 SHARES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purpose of Proposal Four is to increase the authorized number of shares of our common stock from 150,000,000 shares of common stock to
600,000,000 shares of common stock, to be effective as of the date of filing a charter amendment with the Maryland State Department of
Assessments and Taxation (&#8220;SDAT&#8221;), which date shall be determined by our Board of Directors (the &#8220;Amendment&#8221;).&#160;&#160;The
number of issued and outstanding shares of common stock will not change as a result of the Amendment, if effected.&#160;&#160;We currently
have 1,000,000 shares of preferred stock authorized and no shares of preferred stock outstanding.&#160;&#160;The number of authorized,
issued, and outstanding shares of our preferred stock will not change as a result of the Amendment, if effected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Purposes
of the Proposed Amendment</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management and Board of Directors believe that the Amendment is necessary in order to ensure that we have sufficient shares of common
stock to meet our existing obligations, as described in greater detail below, and to provide our company with additional authorized shares
of common stock so that we would have the ability to issue shares from time to time as may be appropriate for proper business purposes,
such as raising additional capital for ongoing operations, establishing strategic relationships, acquiring or investing in complementary
businesses and providing equity incentives to employees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
future issuance of our common stock would remain subject to stockholder approval if required by law or the listing rules of the NYSE
American.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Outstanding
Shares and Existing Obligations to Issue Common Stock</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of August 1, 2025, we had 150,000,000 shares of common stock authorized, 90,809,112 shares of common stock outstanding, and 14,302,146
shares of common stock reserved for issuance upon the vesting or exercising of outstanding restricted awards, including options and units.&#160;&#160;If
all of the Company&#8217;s units and options issued and outstanding as of August 1, 2025, were exercised and converted, the Company would
have 105,111,258 shares of common stock issued and outstanding. In addition, we have an active at-the-market offering pursuant with A.G.P./Alliance
Global Partners (the &#8220;Agent&#8221;) pursuant to which we may offer and sell, from time to time, through the Agent, as sales agent
and/or principal, shares of our common stock having an aggregate offering price of up to $60 million, subject to certain limitations
on the amount of common stock that may be offered and sold by the Company set forth in the Sales Agreement. As of March 31, 2025, the
Company has sold approximately $2.1 million, under the Sales Agreement. We have no current plans, arrangements or understandings for
the issuance of our authorized shares of common stock, except with respect to issuances pursuant to Sales Agreement, vesting of outstanding
awards and the proposals described in this proxy statement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Business
Purposes</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors believes that an increase in our authorized shares of common stock is advisable because such increase will provide
us with the flexibility to meet business needs as they arise and to take advantage of favorable opportunities.&#160;&#160;The increased
number of shares available for issuance would give us the flexibility of using common stock to raise capital and/or as consideration
in acquiring other businesses.&#160;&#160;Such acquisitions may be effected using shares of common stock or other securities convertible
into common stock and/or by using capital that may need to be raised by selling such securities.&#160;&#160;The current number of available
authorized shares of common stock limits our ability to effect acquisitions of businesses using shares of our common stock or issuing
shares to raise capital to fund such acquisitions or for other purposes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
increased number of shares available for issuance may also be used to facilitate public or private financing.&#160;&#160;If required
operating funds cannot be generated by operations, we may need to, among other things, issue and sell unregistered common stock, or securities
convertible into common stock, in private transactions.&#160;&#160;In the future, we may sell common stock at prices less than the public
trading price of the common stock at the time, and we may grant additional contractual rights to purchase the common stock not available
to other holders of common stock, such as warrants to purchase additional shares of common stock or anti-dilution protections.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
increased number of shares available for issuance will also permit us to continue to award stock-based compensation as a viable part
of the Company&#8217;s compensation strategy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 11; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; vertical-align: bottom; width: 0.4in"><img alt="" src="image_002.jpg"/></td><td style="text-align: left; vertical-align: bottom; width: 3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;|&#160;FYE2025 Form PRE 14A</span></td><td style="text-align: right; vertical-align: bottom"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Effects
of Increase</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
additional authorized but unissued shares of common stock may generally be issued from time to time for such proper corporate purposes
as may be determined by our Board of Directors, without further action or authorization by our stockholders, except for some limited
circumstances where stockholder approval is required by law or the listing standards of any stock exchange on which our common stock
may be listed at such time.&#160;&#160;The possible future issuance of shares of equity securities consisting of common stock or securities
convertible into common stock could affect our current stockholders in a number of ways.&#160;&#160;In general, the issuance of new shares
of common stock will cause immediate dilution of the ownership interests of and the voting power of our existing stockholders, may affect
the amount of dividends, if any, paid to such stockholders and may reduce the share of the proceeds of our company that they would receive
upon the future liquidation, if any, of our company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the future issuance of shares of equity securities could:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">dilute
the market price of our common stock, to the extent that the shares of common stock are issued and sold at prices below current trading
prices of the common stock, or if the issuance consists of equity securities convertible into common stock, to the extent that the securities
provide for the conversion into common stock at prices that could be below current trading prices of the common stock;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">dilute
the earnings per share, if any, and book value per share of the outstanding shares of common stock; and</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
the payment of dividends on common stock, if any, potentially more expensive.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
flexibility given to our Board of Directors to issue additional shares of common stock could also enhance our ability to negotiate on
behalf of our stockholders in a takeover situation and have an anti-takeover effect.&#160;&#160;The authorized but unissued shares of
common stock could be used by our Board of Directors to discourage, delay or make more difficult a change in the control of our company.&#160;&#160;For
example, such shares could be privately placed with purchasers who might align themselves with our Board of Directors in opposing a hostile
takeover bid.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of additional shares could serve to dilute the stock ownership of persons seeking to obtain control and thereby increase the
cost of acquiring a given percentage of the outstanding stock.&#160;&#160;Stockholders should be aware that approval of this Proposal
Four could facilitate future efforts by our Board of Directors to deter or prevent changes in control of our company, including transactions
in which the stockholders might otherwise receive a premium for their shares over then current market prices.&#160;&#160;The increase
in our authorized common stock, however, is not being proposed in response to any effort of which we are aware to accumulate shares of
our common stock or to obtain control of our Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
availability of additional shares of common stock is particularly important in the event that our Board of Directors needs to undertake
any of the foregoing actions on an expedited basis and therefore needs to avoid the time (and expense) of seeking stockholder approval
in connection with the contemplated action.&#160;&#160;A copy of the full text of the form of Charter Amendment is attached to this Proxy
Statement as Appendix A.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Effective
Date of the Amendment</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Amendment is approved by our stockholders, the increase in our authorized number of shares of common stock will be effective as of
the date of filing a charter amendment with the SDAT, which shall be determined by our Board of Directors, provided that such time and
date is prior to March 31, 2026.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No
Appraisal Rights</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
Maryland law nor our Amended and Restated Articles of Incorporation or bylaws provide our stockholders with dissenters&#8217; or appraisal
rights in connection with this Amendment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Vote
Required and Board of Directors Recommendation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
approval of the Amendment will require the affirmative vote of the holders of two-thirds (2/3) of the shares of common stock present
or represented at the Annual Meeting and entitled to vote thereat.&#160;&#160;For purposes of the vote on the proposed Amendment, abstentions
and broker non-votes will have the same effect as votes against the proposal.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Board of Directors recommends that you vote FOR the Amendment to increase the authorized number of shares of our common stock to 600,000,000
shares.</b>&#160;&#160;Proxies solicited by management for which no specific direction is included will be voted FOR the increase to
the authorized number of shares to 600,000,000 to shares of the Company&#8217;s common stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>


</div><!-- Field: Page; Sequence: 12; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; vertical-align: bottom; width: 0.4in"><img alt="" src="image_002.jpg"/></td><td style="text-align: left; vertical-align: bottom; width: 3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;|&#160;FYE2025 Form PRE 14A</span></td><td style="text-align: right; vertical-align: bottom"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROPOSAL
FIVE</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THE
ADJOURNMENT PROPOSAL</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
at the Annual Meeting of Stockholders on October 10, 2025 the number of shares of the Company&#8217;s common stock present or represented
and voting in favor of the adoption or rejection of the proposals is insufficient to adopt such proposals under the applicable rules
and regulations, the Company&#8217;s Executive Chairman intends to move to adjourn the Annual Meeting in order to enable our Board of
Directors to solicit additional proxies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this Proposal Five, we are asking you to authorize Mr. Ram Mukunda or Mr. Richard Prins to vote in favor of an adjournment of the Annual
Meeting to another time and place for the purpose of soliciting additional proxies. If the stockholders approve the Adjournment Proposal,
we could adjourn the Annual Meeting, and any adjourned session of the Annual Meeting, and use the additional time to solicit additional
proxies, including the solicitation of proxies from stockholders that have previously submitted proxies. Among other things, approval
of the Adjournment Proposal could mean that, even if we had received proxies representing a sufficient number of votes against some of
the proposals, we could adjourn the Annual Meeting without a vote on that particular proposal and seek to convince the holders of those
shares to change their votes to votes in favor of adoption of such proposal.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our stockholders do not approve the Adjournment Proposal, our Board of Directors may not be able to adjourn the Meeting to a later date
in the event there are not sufficient votes at the time of the Meeting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Vote
Required and Board Recommendation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Adjournment Proposal, if a quorum is present, requires the affirmative vote of a majority of the votes present and entitled to vote.
In the absence of a quorum, the stockholders present, by majority vote, may adjourn the Meeting. Broker non-votes will have no effect
on the outcome of the vote on the Adjournment Proposal.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Board of Directors recommends that you vote FOR the Adjournment Proposal. Proxies solicited by management for which no specific direction
is included will be voted FOR the Adjournment Proposal.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 13; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; vertical-align: bottom; width: 0.4in"><img alt="" src="image_002.jpg"/></td><td style="text-align: left; vertical-align: bottom; width: 3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;|&#160;FYE2025 Form PRE 14A</span></td><td style="text-align: right; vertical-align: bottom"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITY
OWNERSHIP OF BENEFICIAL OWNERS AND MANAGEMENT</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information regarding the beneficial ownership of our common stock as of August 1, 2025, by each person known
by us to be the beneficial owner of more than 5% of our outstanding shares of common stock, each of our executive officers and directors,
and all our officers and directors as a group.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with the rules of the SEC and does not necessarily indicate beneficial ownership for any other
purpose. Under these rules, beneficial ownership includes those shares of common stock over which the stockholder has sole or shared
voting or investment power. It also includes shares of common stock that the stockholder has a right to acquire within 60 days through
the exercise of any option or other right. The percentage ownership of the outstanding common stock, which is based upon shares of common
stock outstanding as of August 1, 2025, is based on the assumption, expressly required by the rules of the SEC, that only the person
or entity whose ownership is being reported has exercised options to purchase shares of our common stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, we believe that all persons named in the table have sole voting and investment power with respect to all shares
of common stock beneficially owned by them. Unless otherwise noted, the nature of the ownership set forth in the table below is the common
stock of the Company. The table below sets forth as of August 1, 2025, except as noted in the footnotes to the table, certain information
with respect to the beneficial ownership of the Company&#8217;s common stock by (i) all persons or groups, according to the most recent
Schedule 13D or Schedule 13G filed with the SEC or otherwise known to us, to be the beneficial owners of more than 5% of the outstanding
common stock of the Company, (ii) each director of the Company, (iii) the executive officers named in the Summary Compensation Table,
and (iv) all such executive officers and directors of the Company as a group.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1pt solid">Name and Address of Beneficial Owners/Named Executive Officers and Directors: (1)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<br/> Shares<br/> Beneficially<br/> Owned</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage<br/> of Class*</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.25pt">Ram Mukunda (2)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,092,678</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4.51</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Claudia Grimaldi</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,184,252</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.30</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Richard Prins</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,271,251</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.40</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">James Moran</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,105,735</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.22</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Terry L. Lierman</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,411</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.03</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Bradbury Strategic Investment Fund A (3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,823,529</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15.22</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0.25pt">All Executive Officers and Directors as a group (5 persons)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">21,506,856</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">23.68</td><td style="font-weight: bold; text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on 90,809,112 shares of common stock outstanding as of August 1, 2025.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, the address of each of the individuals listed in the table is c/o IGC Pharma, Inc., 10224 Falls Road, Potomac, MD
20854.</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
beneficial ownership table does not include 810,752 shares of common stock that are owned by Mr. Mukunda&#8217;s spouse for which Mr.
Mukunda has no voting or financial rights.</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
individual who holds voting and investment power in the investment manager is Mr. Loo See Yuen, the Director of Bradbury Asset Management.
The address of the entity is Unit 5106-7, 51st Floor, The Center, 99 Queen&#8217;s Road Central, Central, Hong Kong.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; vertical-align: bottom; width: 0.4in"><img alt="" src="image_002.jpg"/></td><td style="text-align: left; vertical-align: bottom; width: 3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;|&#160;FYE2025 Form PRE 14A</span></td><td style="text-align: right; vertical-align: bottom"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DIRECTORS,
EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Information
about our executive officers, and directors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
names, ages, and positions of our executive officers and directors as of, were as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.25pt 0.4pt; vertical-align: bottom; width: 25%; border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.25pt 0.4pt; vertical-align: bottom; width: 6%; border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.25pt 0.4pt; vertical-align: bottom; width: 6%; border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.25pt 0.4pt; vertical-align: bottom; width: 40%; border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.25pt 0.4pt; vertical-align: bottom; width: 9%; border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
    Since</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.25pt 0.4pt; vertical-align: bottom; width: 9%; border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Term
    will Expire</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ram Mukunda</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, Chief Executive
    Officer, and Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2005</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard Prins</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board of Directors</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2007</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2027</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James Moran</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terry L. Lierman</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2027</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Claudia Grimaldi</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice President, Principal Financial
    Officer, Chief Compliance Officer, and Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal occupations for the past five years (and, in some instances, for prior years) of each of our executive officers and directors
are set out in Proposal One. There are no family relationships between any of our executive officers or directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
of directors and independence</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors is divided into three classes (Class A, Class B, and Class C) with only one class of directors being elected each
year and each class serving a three-year term. The term of office of the Class A director, consisting of Claudia Grimaldi, will expire
at the 2026 annual meeting of stockholders. The term of office of the Class B directors, currently consisting of Richard Prins and Terry
L. Lierman, will expire at the 2027 annual meeting of stockholders. The term of office of the Class C directors, currently consisting
of Ram Mukunda and James Moran, will expire at the 2025 annual meeting of stockholders. These individuals have played a key role in identifying
and evaluating prospective acquisition candidates, selecting the target businesses, and structuring, negotiating, and consummating acquisitions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NYSE American, upon which our shares are listed, requires the majority of our Board, or in the case of a smaller reporting Company, at
least 50% of our Board, to be &#8220;independent.&#8221; The NYSE American listing standards define an &#8220;independent director&#8221;
generally as a person, other than an officer or an employee of the Company, who does not have a relationship with the Company that would
interfere with the director&#8217;s exercise of independent judgment. Consistent with these standards, the Board of Directors has determined
that Messrs. Prins, Moran, and Lierman are independent directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
leadership structure</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board believes its current leadership structure best serves the objectives of the Board&#8217;s oversight of management, the Board&#8217;s
ability to carry out its roles and responsibilities on behalf of IGC&#8217;s shareholders, and IGC&#8217;s overall corporate governance.
The Board also believes that the separation of the Chairman and CEO roles allows the CEO to focus his time and energy on operating and
managing IGC, while leveraging the Chairman&#8217;s experience and perspectives. The Board periodically reviews its leadership structure
to determine whether it continues to best serve IGC and its shareholders.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
oversight of risk management</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board is responsible for overseeing the major risks facing the Company, while management is responsible for assessing and mitigating
the Company&#8217;s risks on a day-to-day basis. The Board has designated the Audit Committee with the responsibility for overseeing
enterprise risk management. The Audit Committee discusses the steps management has taken to monitor and mitigate these risks, if any.
In establishing and reviewing IGC&#8217;s executive compensation, the Compensation Committee considers whether the compensation program
is focused on long-term shareholder value creation and whether it encourages short-term risk taking at the expense of long-term results.
The Compensation Committee has also reviewed IGC&#8217;s compensation program and has concluded that these programs do not create risks
that are reasonably likely to have a material adverse effect on IGC. Other Board committees also consider risks within their areas of
responsibility and apprise the Board of significant risks and management&#8217;s response to those risks.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 15; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; vertical-align: bottom; width: 0.4in"><img alt="" src="image_002.jpg"/></td><td style="text-align: left; vertical-align: bottom; width: 3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;|&#160;FYE2025 Form PRE 14A</span></td><td style="text-align: right; vertical-align: bottom"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
committee</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors has established an Audit Committee, currently composed of two independent directors who report to the Board of Directors.
Messrs. Prins and Moran, each of whom is an independent director under the NYSE American listing standards, serve as members of our Audit
Committee. Mr. Prins is the Chairman of our Audit Committee. In addition, we have determined that Messrs. Prins and Moran are &#8220;audit
committee financial experts,&#8221; as that term is defined under Item 407 of Regulation S-K. The Audit Committee is responsible for
meeting with our independent accountants regarding, among other issues, audits and the adequacy of our accounting and control systems.
The audit committee charter is followed by the committee.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
committee</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Compensation Committee is comprised of two independent members of the Board of Directors, Richard Prins and James Moran. No executive
officer of the Company served as a director or member of the Compensation Committee of any other entity. The Compensation Committee was
responsible for determining executive compensation and the award of stock and stock options to employees, advisors, and directors during
Fiscal 2025. No consultants were used by the Compensation Committee during this fiscal year.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
committee interlocks and insider participation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Compensation Committee is comprised of two independent members of the Board of Directors, Richard Prins and James Moran. No executive
officer of the Company served as a director or member of the Compensation Committee of any other entity. The Compensation Committee was
responsible for determining executive compensation and the award of stock and stock options to employees, advisors, and directors during
Fiscal 2025. No consultants were used by the Compensation Committee during this fiscal year.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nominating
and corporate governance committee</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the future, we intend to establish a nominating and corporate governance committee. The primary purpose of the nominating and corporate
governance committee will be to identify individuals qualified to become directors, recommend to the Board of Directors the candidates
for election by stockholders or appointment by the Board of Directors to fill a vacancy, recommend to the Board of Directors the composition
and chairs of Board of Directors committees, develop and recommend to the Board of Directors guidelines for effective corporate governance,
and lead an annual review of the performance of the Board of Directors and each of its committees. We do not have any formal process
for stockholders to nominate a director for election to our Board of Directors. Currently, nominations are selected or recommended by
a majority of the independent directors as stated in Section 804(a) of the NYSE American Company Guide. Since the Company is a smaller
reporting company with limited officers and directors, the committee currently does not have a nomination committee charter. The Board
of Director nominations occur by either selection or recommendation of a majority of the independent directors.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disclosure
Committee</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CEO and the PFO supervise and oversee the Disclosure Committee. The Board has appointed Mr. Richard Prins as the Chairperson of the Disclosure
Committee. The Disclosure Committee&#8217;s responsibilities are to design, implement, and regularly evaluate the Company&#8217;s internal
controls and procedures, to ensure that the company provides the stakeholders, including the SEC, security holders, and the investment
community, disclosures that comply with regulations and other compliance obligations. The Disclosure Committee will review all required
material and relevant reports related to disclosure statements, including annual reports on Form 10-K, quarterly reports on Form 10-Q,
press releases, and social media containing financial information and other related public documents. The Disclosure Committee meets
not less than once per quarter and reviews and reassesses the adequacy of the Disclosure Committee&#8217;s Charter at least annually.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership
Guidelines</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
align the interests of the Board of Directors directly with the interests of the stockholders, the Committee recommends that each Board
member maintain a minimum ownership interest in our Company. We have implemented IGC&#8217;s Stock Ownership Guidelines requiring directors
to retain ownership of 35% of the common stock that they receive upon joining the Board, if any, and that they receive as part of any
compensation during their tenure on the Board, if any, except that the Stock Ownership Guidelines shall not apply where a director transfers
stock to a personal trust(s) or makes a gift.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; vertical-align: bottom; width: 0.4in"><img alt="" src="image_002.jpg"/></td><td style="text-align: left; vertical-align: bottom; width: 3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;|&#160;FYE2025 Form PRE 14A</span></td><td style="text-align: right; vertical-align: bottom"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
Committee Financial Expert</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee will at all times be composed exclusively of &#8220;independent directors&#8221; who are &#8220;financially literate,&#8221;
as defined under the NYSE American listing standards, who understand the audit committee functions. The NYSE American&#8217;s listing
standards define &#8220;financially literate&#8221; as being able to read and understand fundamental financial statements, including
a company&#8217;s balance sheet, income statement, and cash flow statement. In addition, we must certify to the NYSE American that the
Audit Committee has, and will continue to have, at least one member who has past employment experience in finance, accounting, or auditing,
requisite professional certification in accounting, or other comparable experience or background that results in the individual&#8217;s
financial sophistication, along with an understanding of internal control over financial reporting. The Board of Directors has determined
that Messrs. Prins and Moran satisfy the NYSE American&#8217;s definition of financial sophistication and qualify as &#8220;audit committee
financial experts,&#8221; as defined under the rules and regulations of the SEC.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
and committee meetings</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
Fiscal 2025, there were six (6) Board meetings, five (5) meetings of the Audit Committee, and two (2) Compensation Committee meetings,
all of which were attended, either in person or telephonically, by all our directors of the Board and all of the members of the committees,
respectively.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Communications
with the Board</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
matter intended for the Board or any individual member of the Board should be directed to Investor Relations at the Company&#8217;s principal
executive office, with a request to forward the communication to the intended recipient. In general, any shareholder communication delivered
to the Company for forwarding to Board members will be forwarded in accordance with the shareholder&#8217;s instructions. However, the
Company reserves the right not to forward to Board members any abusive, threatening, or otherwise inappropriate materials.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indemnification
agreements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are party to indemnification agreements with each of the executive officers and directors. Such indemnification agreements require us
to indemnify these individuals to the fullest extent permitted by law. Under the terms of the indemnification agreements, we intend to
agree to indemnify our officers and directors against expenses, judgments, fines, penalties, or other amounts actually and reasonably
incurred by the independent director in connection with any proceeding if the officer or director acted in good faith and did not derive
an improper personal benefit from the transaction or occurrence that is the basis of the proceeding.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Annual
meeting attendance</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
directors, either in person or telephonically, attended the 2024 annual shareholder&#8217;s meeting. We have a formal policy requiring
the members of our Board of Directors to attend annual stockholder meetings in person or by telephone or video conference.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
governance, code of conduct and ethics</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
code of business conduct and ethics is a written standard designed to deter wrongdoing and to promote (a) honest and ethical conduct,
(b) full, fair, accurate, timely, and understandable disclosure in regulatory filings and public statements, (c) compliance with applicable
laws, rules, and regulations, (d) the prompt reporting violation of the code and (e) accountability for adherence to the code. The Company
has adopted a written code of ethics (the &#8220;Code of Ethics&#8221;) that applies to the Company&#8217;s Chief Executive Officer and
senior financial officers, including the Company&#8217;s Principal Accounting Officer, Controller, and persons performing similar functions
(collectively, the &#8220;Senior Financial Officers&#8221;), in accordance with applicable federal securities laws and the rules of the
NYSE American, and to all employees. Investors or any other person may view our Code of Ethics free of charge on the corporate governance
subsection of the investor relations portion of our website at www.igcinc.us. The Company has established separate audit and compensation
committees that are described elsewhere in this report. The Company does not have a separate nominating committee. Accordingly, Board
of Director nominations occur by either selection or recommendation of a majority of the independent directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
our data, except accounting data, is stored in the cloud on multiple servers, which helps us mitigate the overall risk of losing data.
As part of corporate governance, we also have a cybersecurity policy that employees are required to comply with to safeguard their systems
from cyber-attacks.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; vertical-align: bottom; width: 0.4in"><img alt="" src="image_002.jpg"/></td><td style="text-align: left; vertical-align: bottom; width: 3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;|&#160;FYE2025 Form PRE 14A</span></td><td style="text-align: right; vertical-align: bottom"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
and Officer Derivative Trading and Hedging Policy</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has adopted a policy which prohibits our officers, non-employee directors, and key personnel from purchasing financial instruments
(including prepaid variable forward contracts, equity swaps, collars, and exchange funds), or otherwise engage in transactions, that
hedge or offset, or are designed to hedge or offset, any decrease in the market value of our common stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Insider
Trading Policy</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" id="ixv-4118">We
have an insider trading policy</ix:nonNumeric> governing the purchase, sale, and other dispositions of our securities (the &#8220;Insider Trading Policy&#8221;)
that applies to all of our directors, officers, employees, and other covered persons identified within the Insider Trading Policy. We
believe that the Insider Trading Policy is reasonably designed to promote compliance with applicable U.S. federal securities laws, rules,
and regulations, as well as applicable listing standards relating to insider trading. In addition, with regard to our trading in our
own securities, it is our policy to comply with applicable federal securities laws and applicable listing requirements. The Insider Trading
Policy is filed as Exhibit 19.1 to the Company&#8217;s Annual Report on Form 10-K for fiscal year 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delinquent
Section 16(a) reports</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
16(a) of the Securities and Exchange Act of 1934, as amended, requires our officers, directors, and beneficial owners of more than 10%
of our equity securities to timely file certain reports regarding ownership of and transactions in our securities with the Securities
and Exchange Commission. Copies of the required filings must also be furnished to us. Section 16(a) compliance was required during Fiscal
2025. Based solely on a review of Forms 3, 4, and 5 and amendments thereto furnished to us pursuant to Rule 16a-3(e) under the Exchange
Act, we believe that Fiscal 2025&#8217;s filing requirements under Section 16(a) of the Exchange Act have been satisfied, except for
(1) a Form 5 for Claudia Grimaldi reporting the vesting of RSUs on March 31, 2025; (2) a Form 5 for James Moran reporting the vesting
of RSUs on March 31, 2025, (3) a Form 5 for Ram Mukunda reporting the vesting of RSUs on March 31, 2025 and (4) a Form 5 for Richard
Prins reporting the vesting of RSUs on March 31, 2025.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
for Executive Officers of the Company</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information concerning all cash and non-cash compensation awarded to, earned by, or paid to (i) all individuals
serving as the smaller reporting company&#8217;s principal executive officer or acting in a similar capacity during the last completed
fiscal year (PEO), regardless of compensation level; (ii) the smaller reporting company&#8217;s two most highly compensated executive
officers other than the PEO who was serving as executive officers at the end of the last completed fiscal year and whose compensation
exceeded $100,000.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Compensation Table</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(in
thousands)</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Name and Principal Position</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Salary<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Bonus<br/> ($)(1)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock <br/> Awards&#160;(2)<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Other <br/> compensation&#160;(3)<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total<br/> Compensation<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%; text-align: left; padding-left: 0.25pt">Ram Mukunda</td><td style="width: 1%">&#160;</td>
    <td style="width: 7%; text-align: center; padding-left: 0.25pt">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">396</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">92</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">80</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">568</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">President and CEO</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 0.25pt">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">360</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">320</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,066</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,821</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Claudia Grimaldi</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 0.25pt">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">226</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">259</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Vice President, CCO, and PFO</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 0.25pt">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">198</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">112</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">370</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">717</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
fiscal 2025, the outstanding bonus of Ram Mukunda of approximately $423 thousand and of Claudia Grimaldi of approximately $327 thousand
has been converted into performance-based bonuses and will be paid upon achieving the following milestones. Completion of CALMA Phase
2 Clinical Trial; 2. Successful fundraising of at least $5 million via equity, debt, partnerships, or non-dilutive grants.</span></td>
</tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Stock Awards represent the fair value of stock awards to the named executive officer as computed using the closing price at the day of
grant or using an appropriate pricing model depending on the terms of the award. The Stock Awards include vested and unvested grants
of stock awards as reflected in the table titled &#8220;Stock Awards at Fiscal Year End.&#8221;&#160;&#160;This also includes two categories
of Stock Awards that are set out in the tables titled &#8220;Performance-Based Stock Awards&#8221; and &#8220;Market Price-Based Stock
Awards,&#8221; which account for approximately $689 thousand in fiscal 2024 and Nil in fiscal 2025.</span></td>
</tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
life insurance, 401 (k) contribution, health insurance(s) and other applicable compensation.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; vertical-align: bottom; width: 0.4in"><img alt="" src="image_002.jpg"/></td><td style="text-align: left; vertical-align: bottom; width: 3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;|&#160;FYE2025 Form PRE 14A</span></td><td style="text-align: right; vertical-align: bottom"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
to Directors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(in
thousands)</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
fiscal 2025, no compensation was awarded to, earned by, or paid to non-employee directors who served on the Board during the fiscal year.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Stock Awards at Fiscal Year End</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(in
thousands)</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<br/> unvested <br/> Stock <br/> Awards (#)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Value of <br/> unvested<br/> Stock <br/> Awards ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.25pt">Ram Mukunda</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,527</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,200</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Claudia Grimaldi</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,203</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">371</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Richard Prins</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">936</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">540</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">James Moran</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">294</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Terry L. Lierman</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Stock Awards reflect the grant date fair value, in accordance with Accounting Standards Codification (ASC) Topic 718, Compensation &#8212;
Stock Compensation (formerly Statement of Financial Accounting Standards (SFAS) No. 123R) for awards pursuant to the Company&#8217;s
equity incentive program.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included
in the tables above are two categories of Stock Awards: (i) performance-based stock awards that are based on achieving milestones in
the area of drug development; and (ii) market price-based awards, based on advancing the IGC stock price.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
contracts</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ram
Mukunda has served as President and Chief Executive Officer of our Company since its inception. On November 18, 2021, the Company, and
Mr. Mukunda entered into the 2021 CEO Employment Agreement that expires on November 17, 2026. Pursuant to the 2021 CEO Employment Agreement,
we pay Mr. Mukunda a base salary of $360,000 per year. The Employment Agreement provides that the Board of Directors of our Company may
review and update the targets and amounts for the net revenue and salary and contract bonuses on an annual basis. Mr. Mukunda is entitled
to benefits, including insurance, participation in company-wide 401(k), reimbursement of business expenses, 20 days of annual paid vacation,
sick leave, domestic help, driver, cook, and a car (subject to partial reimbursement by Mr. Mukunda of rental payments for the car and
reimbursement of business expenses). In the event of termination without cause, including a change of control, we would be required to
pay Mr. Mukunda 1.5 times the average of the total compensation as disclosed in the previous two 10-K filings prior to termination. In
addition, all unvested shares would be subject to immediate vesting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Claudia
Grimaldi has served as Vice President, Principal Financial Officer, Chief Compliance Officer, and Director of our subsidiaries since
May 9, 2018. On May 5, 2023, the Company and Ms. Grimaldi entered into an Employment Agreement that expires on May 8, 2028 (the 2023
Employment Agreement). Pursuant to the Employment Agreement, we pay Ms. Grimaldi a base salary of $200,000 per year. The Employment Agreement
provides that the Company may review and update performance targets and contract bonuses on an annual basis. Ms. Grimaldi is entitled
to benefits, including insurance, participation in company-wide 401(k), reimbursement of business expenses, 20 days of annual paid vacation,
sick leave, and a car (subject to partial reimbursement by Ms. Grimaldi for personal use of the car). In the event of termination without
cause, including a change of control, we would be required to pay Ms. Grimaldi 1.5 times her compensation. In addition, unvested shares
that would otherwise vest in a 12-month period would be subject to immediate vesting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
non-employee directors, the Company has a standard compensation arrangement such as fees for committee service, service as chairman of
the board, or a committee, and meeting attendance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
risk assessment</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
setting compensation, the Compensation Committee considers the risks to our stockholders and to the achievement of our goals that may
be inherent in our compensation programs. The Compensation Committee reviewed and discussed its assessment with management and concluded
that our compensation programs are within industry standards and are designed with the appropriate balance of risk and reward to align
employees&#8217; interests with those of our Company and do not incent employees to take unnecessary or excessive risks. Although a portion
of our executives&#8217; and employees&#8217; compensation is performance-based and &#8220;at risk,&#8221; we believe our compensation
plans are appropriately structured and are not reasonably likely to result in a material adverse effect on our Company.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 19; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; vertical-align: bottom; width: 0.4in"><img alt="" src="image_002.jpg"/></td><td style="text-align: left; vertical-align: bottom; width: 3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;|&#160;FYE2025 Form PRE 14A</span></td><td style="text-align: right; vertical-align: bottom"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Policies
and practices related to the grant of equity awards close in time to the release of material nonpublic information</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" escape="true" name="ecd:AwardTmgMnpiDiscTextBlock" id="ixv-4119">Neither
the Board nor the Compensation Committee takes material nonpublic information into account when determining the timing or terms of equity
awards, including with respect to options, nor do we time the disclosure of material nonpublic information for the purpose of affecting
the value of executive compensation.</ix:nonNumeric> Although <ix:nonNumeric contextRef="c0" escape="true" name="ecd:AwardTmgHowMnpiCnsdrdTextBlock" id="ixv-4120">we <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="ecd:MnpiDiscTimedForCompValFlag" id="ixv-4121"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="ecd:AwardTmgMnpiCnsdrdFlag" id="ixv-4122">do not</ix:nonNumeric></ix:nonNumeric> have a formal policy with respect to the timing of our equity award grants, <ix:nonNumeric contextRef="c0" escape="true" name="ecd:AwardTmgMethodTextBlock" id="ixv-4123">we
have generally granted such awards once a year to directors and executive officers, and equity awards may be granted at other times during
the year to newly hired or promoted employees, and in other special circumstances.</ix:nonNumeric> In fiscal 2025, we did not grant any stock options,
stock appreciation rights, or similar option-like instruments.</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pay
versus performance disclosure</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(v) of Regulation S-K, we are
providing the following information about the relationship between executive compensation actually paid (as defined by SEC rules) and
certain financial and operational performances of the Company.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee did not consider the pay versus performance disclosure when making its compensation decisions for the 2025 fiscal
year. The amounts in the table below are calculated in accordance with SEC rules and do not represent amounts actually earned or realized
by our named executive officers. As required by Item 402(v) of Regulation S-K, we are providing the following information about the relationship
between executive compensation actually paid and certain financial and operational performance of the Company for each of the last three
completed fiscal years. In determining the &#8220;compensation actually paid&#8221; or realized compensation (&#8220;CAP&#8221;) to our
other Named Executive Officers (&#8220;NEO&#8221;), we are required to make various adjustments to amounts that have been previously
reported in the Summary Compensation Table in previous years, as the SEC&#8217;s valuation methods for this section differ from those
required in the Summary Compensation Table (&#8220;SCT&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes compensation values both previously reported in our SCT, as well as the adjusted values required in this section
for Fiscal 2025, 2024, and 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_PvpTableTextBlock-c0_cont_1" escape="true" name="ecd:PvpTableTextBlock" id="ixv-2811"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pay
Versus Performance Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(in
thousands)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included
in the table below is the annual compensation paid to our executives and our financial performance for each of the three previous years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Summary<br/> Compensation <br/>
Table <br/>
Total for <br/>
PEO(1)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Compensation <br/>
Actually <br/>
Paid to <br/>
PEO(3)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Average <br/>
Summary <br/>
Compensation <br/>
Table <br/>
Total for <br/>
Non-PEO <br/>
NEOs <br/>
Officer(2)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Average <br/>
Compensation <br/>
Actually <br/>
Paid to <br/>
Non-PEO <br/>
NEOs(3)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Value of <br/>
Initial <br/>
Fixed $100 <br/>
Investment <br/>
Based On: <br/>
Total <br/>
Shareholder <br/>
Return(4)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Net Income <br/>
(Loss)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">(a)</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">(b)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">(c)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">(d)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">(e)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">(f)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">(g)</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%; text-align: center; padding-left: 0.25pt">2025</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ecd:PeoTotalCompAmt" scale="3" unitRef="usd" id="ixv-4124">568</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ecd:PeoActuallyPaidCompAmt" scale="3" sign="-" unitRef="usd" id="ixv-4125">203</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ecd:NonPeoNeoAvgTotalCompAmt" scale="3" unitRef="usd" id="ixv-4126">259</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" scale="3" unitRef="usd" id="ixv-4127">78</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ecd:TotalShareholderRtnAmt" scale="3" unitRef="usd" id="ixv-4128">70</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-4129">7,121</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: center; padding-left: 0.25pt">2024</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="ecd:PeoTotalCompAmt" scale="3" unitRef="usd" id="ixv-4130">1,821</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="ecd:PeoActuallyPaidCompAmt" scale="3" unitRef="usd" id="ixv-4131">2,699</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="ecd:NonPeoNeoAvgTotalCompAmt" scale="3" unitRef="usd" id="ixv-4132">717</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" scale="3" unitRef="usd" id="ixv-4133">979</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="ecd:TotalShareholderRtnAmt" scale="3" unitRef="usd" id="ixv-4134">118</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-4135">13,000</ix:nonFraction></td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-left: 0.25pt">2023</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ecd:PeoTotalCompAmt" scale="3" unitRef="usd" id="ixv-4136">1,006</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ecd:PeoActuallyPaidCompAmt" scale="3" sign="-" unitRef="usd" id="ixv-4137">1,453</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ecd:NonPeoNeoAvgTotalCompAmt" scale="3" unitRef="usd" id="ixv-4138">320</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" scale="3" unitRef="usd" id="ixv-4139">103</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ecd:TotalShareholderRtnAmt" scale="3" unitRef="usd" id="ixv-4140">33</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-4141">11,927</ix:nonFraction></td><td style="text-align: left">)</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_NamedExecutiveOfficersFnTextBlock-c0_cont_1" escape="true" name="ecd:NamedExecutiveOfficersFnTextBlock" id="ixv-2973"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
fiscal years 2025, 2024, and 2023, this is the total compensation, as disclosed in the Summary Compensation Table above, for <ix:nonNumeric contextRef="c2" name="ecd:PeoName" id="ixv-4142"><ix:nonNumeric contextRef="c1" name="ecd:PeoName" id="ixv-4143"><ix:nonNumeric contextRef="c0" name="ecd:PeoName" id="ixv-4144">Mr. Ram
Mukunda</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric>, our Principal Executive Officer (&#8220;PEO&#8221;).</span></td>
</tr></table></ix:nonNumeric>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<ix:continuation id="_NamedExecutiveOfficersFnTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
fiscal years 2025, 2024, and 2023, this is the total compensation, as disclosed in the Summary Compensation Table above, for Ms. Claudia
Grimaldi, our non-PEO NEO.</span></td>
</tr></table></ix:continuation>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><ix:nonNumeric contextRef="c0" escape="true" name="ecd:Additional402vDisclosureTextBlock" id="ixv-2997"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
Actually Paid is the Summary Compensation Table total for the PEO (column (b) above) and Summary Compensation Table total for the Non-PEO
(column (d) above), as applicable, with the adjustments pursuant to Item 402(v)(2)(iii)(C) of Regulations S-K.</span></ix:nonNumeric></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The&#160;Total
Shareholder Return reflected in this column for each applicable fiscal year is calculated based on a fixed investment of $100 through
the end of the applicable fiscal year on the same cumulative basis.</span></td>
</tr></table></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 20; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; vertical-align: bottom; width: 0.4in"><img alt="" src="image_002.jpg"/></td><td style="text-align: left; vertical-align: bottom; width: 3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;|&#160;FYE2025 Form PRE 14A</span></td><td style="text-align: right; vertical-align: bottom"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="_PvpTableTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="ecd:AdjToPeoCompFnTextBlock" id="ixv-3028"><ix:nonNumeric contextRef="c0" escape="true" name="ecd:AdjToNonPeoNeoCompFnTextBlock" id="ixv-3029"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">FYE 2025</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">FYE 2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">FYE 2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">FYE 2025</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">FYE 2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">FYE 2023</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">PEO</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">PEO</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">PEO</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-PEO</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-PEO</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-PEO</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; width: 28%; font-weight: bold; text-align: left; padding-left: 0.125in">SCT Total Compensation</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ecd:PeoTotalCompAmt" scale="3" unitRef="usd" id="ixv-4145">568</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="ecd:PeoTotalCompAmt" scale="3" unitRef="usd" id="ixv-4146">1,821</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ecd:PeoTotalCompAmt" scale="3" unitRef="usd" id="ixv-4147">1,006</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ecd:NonPeoNeoAvgTotalCompAmt" scale="3" unitRef="usd" id="ixv-4148">259</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="ecd:NonPeoNeoAvgTotalCompAmt" scale="3" unitRef="usd" id="ixv-4149">717</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ecd:NonPeoNeoAvgTotalCompAmt" scale="3" unitRef="usd" id="ixv-4150">320</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Subtract: Grant date fair value of equity awards granted during the covered year</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:fixed-zero" name="ecd:AdjToCompAmt" scale="3" unitRef="usd" id="ixv-4151">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="3" sign="-" unitRef="usd" id="ixv-4152">1,066</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="3" sign="-" unitRef="usd" id="ixv-4153">301</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:fixed-zero" name="ecd:AdjToCompAmt" scale="3" unitRef="usd" id="ixv-4154">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="3" sign="-" unitRef="usd" id="ixv-4155">370</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="3" sign="-" unitRef="usd" id="ixv-4156">75</ix:nonFraction></td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Add: Fair value as of the end of the covered fiscal year of all awards granted during the covered fiscal year that were outstanding and unvested as of the end of the fiscal covered year;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:fixed-zero" name="ecd:AdjToCompAmt" scale="3" unitRef="usd" id="ixv-4157">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="3" unitRef="usd" id="ixv-4158">1,517</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="3" unitRef="usd" id="ixv-4159">159</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:fixed-zero" name="ecd:AdjToCompAmt" scale="3" unitRef="usd" id="ixv-4160">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="3" unitRef="usd" id="ixv-4161">535</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="3" unitRef="usd" id="ixv-4162">40</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Add: Change in fair value from the end of the prior fiscal year to the end of the covered fiscal year for awards granted in any prior fiscal year that were outstanding and unvested as of the end of the covered fiscal year</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="3" sign="-" unitRef="usd" id="ixv-4163">663</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="3" unitRef="usd" id="ixv-4164">158</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="3" sign="-" unitRef="usd" id="ixv-4165">1,804</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="3" sign="-" unitRef="usd" id="ixv-4166">148</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="3" unitRef="usd" id="ixv-4167">10</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="3" sign="-" unitRef="usd" id="ixv-4168">129</ix:nonFraction></td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Add: Fair value as of the vesting date of awards that were granted and vested in the same year</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:fixed-zero" name="ecd:AdjToCompAmt" scale="3" unitRef="usd" id="ixv-4169">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="3" unitRef="usd" id="ixv-4170">234</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="3" unitRef="usd" id="ixv-4171">79</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:fixed-zero" name="ecd:AdjToCompAmt" scale="3" unitRef="usd" id="ixv-4172">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="3" unitRef="usd" id="ixv-4173">78</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="3" unitRef="usd" id="ixv-4174">20</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Add: Change in fair value from the end of the prior fiscal year to the vesting date of awards granted in any prior fiscal year that vested in the covered fiscal year</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="3" sign="-" unitRef="usd" id="ixv-4175">108</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="3" unitRef="usd" id="ixv-4176">34</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="3" sign="-" unitRef="usd" id="ixv-4177">592</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="3" sign="-" unitRef="usd" id="ixv-4178">33</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="3" unitRef="usd" id="ixv-4179">8</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="3" sign="-" unitRef="usd" id="ixv-4180">72</ix:nonFraction></td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Subtract: Fair value at the end of the prior fiscal year of awards granted in any prior fiscal year that failed to vest (forfeited) in the covered fiscal year</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:fixed-zero" name="ecd:AdjToCompAmt" scale="3" unitRef="usd" id="ixv-4181">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:fixed-zero" name="ecd:AdjToCompAmt" scale="3" unitRef="usd" id="ixv-4182">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:fixed-zero" name="ecd:AdjToCompAmt" scale="3" unitRef="usd" id="ixv-4183">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:fixed-zero" name="ecd:AdjToCompAmt" scale="3" unitRef="usd" id="ixv-4184">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:fixed-zero" name="ecd:AdjToCompAmt" scale="3" unitRef="usd" id="ixv-4185">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:fixed-zero" name="ecd:AdjToCompAmt" scale="3" unitRef="usd" id="ixv-4186">-</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Add: Dollar amount of dividends or other earnings paid on equity awards in the covered fiscal year prior to the vesting date that are not included in total compensation for the covered fiscal year</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:fixed-zero" name="ecd:AdjToCompAmt" scale="3" unitRef="usd" id="ixv-4187">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:fixed-zero" name="ecd:AdjToCompAmt" scale="3" unitRef="usd" id="ixv-4188">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c41" decimals="-3" format="ixt:fixed-zero" name="ecd:AdjToCompAmt" scale="3" unitRef="usd" id="ixv-4189">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c42" decimals="-3" format="ixt:fixed-zero" name="ecd:AdjToCompAmt" scale="3" unitRef="usd" id="ixv-4190">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c43" decimals="-3" format="ixt:fixed-zero" name="ecd:AdjToCompAmt" scale="3" unitRef="usd" id="ixv-4191">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:fixed-zero" name="ecd:AdjToCompAmt" scale="3" unitRef="usd" id="ixv-4192">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; font-weight: bold; text-align: left; padding-left: 0.125in">Compensation Actually Paid</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ecd:PeoActuallyPaidCompAmt" scale="3" sign="-" unitRef="usd" id="ixv-4193">203</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="ecd:PeoActuallyPaidCompAmt" scale="3" unitRef="usd" id="ixv-4194">2,699</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ecd:PeoActuallyPaidCompAmt" scale="3" sign="-" unitRef="usd" id="ixv-4195">1,453</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" scale="3" unitRef="usd" id="ixv-4196">78</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" scale="3" unitRef="usd" id="ixv-4197">979</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" scale="3" unitRef="usd" id="ixv-4198">103</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr> </table></ix:nonNumeric></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relationships
Between Executive Compensation Actually Paid and the Company</b>&#8217;<b>s Financial and Operational Performance Measures</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors and Compensation Committee generally seek to align the interests of stockholders with our named executive officers
by incentivizing long-term performance and through the use of short-term cash incentives. Therefore, we do not specifically align our
performance measures with &#8220;compensation actually paid&#8221; (as computed in accordance with Item 402(v) of Regulation S-K) for
a particular year, and the Compensation Committee did not consider this information in making its executive compensation decisions. Instead,
our executives are paid based on the achievement of a set of predetermined corporate milestones, which are focused on driving long-term
stockholder value. Our executives are compensated at least annually with service-based restricted stock units or stock options to ensure
that their interests are aligned with those of our stockholders. In accordance with Item 402(v) of Regulation S-K, we are providing the
following descriptions of the relationships between the information presented in the Pay Versus Performance table.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c45" escape="true" name="ecd:CompActuallyPaidVsOtherMeasureTextBlock" id="ixv-3323"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Relationship
Between Compensation Actually Paid and Operational Milestones</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not look to net income (loss) as a performance measure for its executive compensation program and instead looks at operational
metrics, such as drug development milestones, pipeline progress, R&amp;D spend, regulatory compliance, intellectual property, partnerships,
collaborations, and general financial health of the Company. The compensation actually paid for both our PEO and non-PEO NEO decreased
between the 2024 fiscal year and Fiscal 2025. This is primarily because the compensation is structured with stock, and the stock did
not perform well despite meeting operational milestones.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation actually paid to our named executive officers from Fiscal 2025 versus the 2024 fiscal year generally reflects cash bonuses
and stock awards, some of which vest based on milestones and others based on time. In addition, the Company decreased operating loss
reflecting a diligent commitment to the financial health of the Company.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock" id="ixv-3339"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Relationship
Between Compensation Actually Paid and Company Total Shareholder Return</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Part
of the overall compensation is the stock price. In fiscal years 2025 and 2024, the metrics set by the Compensation Committee and the
Board with respect to stock price were not met. The PEO and non-PEO were therefore compensated based on shareholder return or value of
stock during the fiscal year in each of the 2025 and 2024 fiscal years in the form of stock awards based on market-based milestones.
These stock milestones are described under the Narrative to Summary Compensation Table section of this Proxy Statement.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 21; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; vertical-align: bottom; width: 0.4in"><img alt="" src="image_002.jpg"/></td><td style="text-align: left; vertical-align: bottom; width: 3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;|&#160;FYE2025 Form PRE 14A</span></td><td style="text-align: right; vertical-align: bottom"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than as described below, during the last two fiscal years, we have not entered into any material transactions or series of transactions
that would be considered material in which any officer, director, or beneficial owner of 5% or more of any class of our capital stock,
or any immediate family member of any of the preceding persons, had direct or indirect material interest, nor are there any such transactions
presently proposed, other than the agreements with the affiliates of our CEO as described under &#8220;Executive Compensation &#8211;
Compensation for Executive Officers of the Company.&#8221;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Review,
approval, or ratification of related party transactions</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a written policy for the review and approval of transactions with related persons. It is our policy for the disinterested members
of our Board to review all related party transactions on a case-by-case basis. To receive approval, a related-party transaction must
have a business purpose for us and be on terms that are fair and reasonable to us and as favorable to us as would be available from non-related
entities in comparable transactions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>Transaction
with Related Parties</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 22, 2024, the Company entered into the SPA with Bradbury Strategic Investment Fund A, resulting in approximately $3 million in
gross proceeds. The completion of the private placement is subject to customary closing conditions, including approval by the NYSE. Under
the terms of the private placement, IGC will issue approximately 8.8 million shares of unregistered common stock at a price of $0.34
per share.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no related party transactions in Fiscal 2025 and through the date of this proxy statement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AUDIT
INFORMATION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
Accountant Fees and Services</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manohar
Chowdhry &amp; Associates (MCA) is our Principal Independent Registered Public Accounting Firm engaged to examine our financial statements
for Fiscal 2025. During the Company&#8217;s two most recent fiscal years ended March 31, 2025, and 2024, and through July 6, 2023, the
Company did not consult with MCA on (i) the application of accounting principles to a specified transaction, either completed or proposed,
or the type of audit opinion that may be rendered on the Company&#8217;s financial statements, and MCA has not provided either a written
report or oral advice to the Company that was an important factor considered by the Company in reaching a decision as to any accounting,
auditing, or financial reporting issue; or (ii) the subject of any disagreement, as defined in Item 304(a)(1)(iv) of Regulation S-K and
the related instructions, or a reportable event within the meaning set forth in Item 304(a)(1)(v) of Regulation S-K.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
related and other fees</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below shows the fees that we paid or accrued for the audit and other services provided by Manohar Chowdhry &amp; Associates for
Fiscal 2025 and Fiscal 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Audit
fees</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
category includes the audit of our annual financial statements, review of financial statements included in our annual and quarterly reports
and services that are normally provided by the independent registered public accounting firms in connection with engagements for those
fiscal years. This category also includes advice on audit and accounting matters that arose during, or as a result of, the audit or the
review of interim financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Internal
control audit fees</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
category includes the audit of the Company&#8217;s internal control over financial reporting based on criteria established in Internal
Control&#8212;Integrated Framework: (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Audit-related
fees</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
category consists of assurance and related services by the independent registered public accounting firms that are reasonably related
to the performance of the audit or review of our financial statements and are not reported above under &#8220;Audit Fees.&#8221; The
services for the fees disclosed under this category include services relating to our registration statement and consultation regarding
our correspondence with the SEC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><!-- Field: Page; Sequence: 22; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; vertical-align: bottom; width: 0.4in"><img alt="" src="image_002.jpg"/></td><td style="text-align: left; vertical-align: bottom; width: 3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;|&#160;FYE2025 Form PRE 14A</span></td><td style="text-align: right; vertical-align: bottom"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Tax
fees</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
category consists of professional services rendered for tax compliance, tax planning, and tax advice. These services include tax return
preparation and advice on state and local tax issues.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>All
other fees</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
category consists of fees for other miscellaneous items.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; font-style: italic">&#160;</td>
    <td colspan="6" style="font-weight: bold; font-style: italic; text-align: center">(in thousands)</td><td style="font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.25pt">Audit fees - Manohar Chowdhry &amp; Associates</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">69</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">69</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Audit-related fees - Manohar Chowdhry &amp; Associates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Tax fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">All other fees</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.25pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">69</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">78</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 23; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; vertical-align: bottom; width: 0.4in"><img alt="" src="image_002.jpg"/></td><td style="text-align: left; vertical-align: bottom; width: 3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;|&#160;FYE2025 Form PRE 14A</span></td><td style="text-align: right; vertical-align: bottom"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Policy
on pre-approval of audit and permissible non-audit services of independent auditors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consistent
with SEC policies regarding auditor independence, the audit committee of our Board of Directors has responsibility for appointing, setting
compensation, and overseeing the work of the independent auditor. In recognition of this responsibility, our Board of Directors has established
a policy to pre-approve all audit and permissible non-audit services provided by the independent auditor. Prior to the engagement of
the independent auditor for the next year&#8217;s audit, management may submit, if necessary, an aggregate of services expected to be
rendered during that year for each of the following four categories of services to our Board of Directors for approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
services include audit work performed in the preparation of financial statements and audit of internal controls, as well as work that
generally only the independent auditor can reasonably be expected to provide, including comfort letters, statutory audits, and attest
services and consultation regarding financial accounting and/or reporting standards.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit-Related
services are for assurance and related services that are traditionally performed by the independent auditor, including due diligence
related to mergers and acquisitions, employee benefit plan audits, and special procedures required to meet certain regulatory requirements.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
services include all services performed by the independent auditor&#8217;s tax personnel except those services specifically related to
the audit of the financial statements and include fees in the areas of tax compliance, tax planning, and tax advice.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
Fees are those associated with services not captured in the other categories.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to engagement, our Board of Directors pre-approves these services by category of service. The fees are budgeted, and our Board of Directors
requires the independent auditor and management to report actual fees versus the budget periodically throughout the year by category
of service. During the year, circumstances may arise when it may become necessary to engage the independent auditor for additional services
not contemplated in the original pre-approval. In those instances, our Board of Directors requires specific pre-approval before engaging
the independent auditor.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit committee may delegate pre-approval authority to one or more of its members. The member to whom such authority is delegated must
report, for informational purposes only, any pre-approval decisions to our Board of Directors at its next scheduled meeting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pre-approved
services</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee&#8217;s charter provides for pre-approval of audit, audit-related, and tax services to be performed by the independent
auditors. The Audit Committee approved the audit, audit-related, and tax services to be performed by independent auditors and tax professionals
in Fiscal 2025. The charter also authorizes the Audit Committee to delegate to one or more of its members pre-approval authority with
respect to permitted services. The decisions of any Audit Committee member to whom pre-approval authority is delegated must be presented
to the full Audit Committee at its next scheduled meeting. The Audit Committee has not delegated such authority to its members.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
committee report</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee of the Board is composed of two directors, each of whom meets the current NYSE American test for independence. The Committee
acts under a written charter adopted by the Board. The Audit Committee has prepared the following report on its activities with respect
to the Company&#8217;s audited financial statements for Fiscal 2025 (the Audited Financial Statements):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee reviewed and discussed the Company&#8217;s Audited Financial Statements with management;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee discussed with Manohar Chowdhry &amp; Associates, the Company&#8217;s independent auditors for Fiscal 2025, the matters
required to be discussed by AS 1300, as adopted by the Public Company Accounting Oversight Board;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee received from the independent auditors the written disclosures regarding auditor independence and the letter required
by Independence Standards Board Standard No. 1 (Independence Discussions with Audit Committees), discussed with Manohar Chowdhry &amp;
Associates, its independence from the Company and its management, and considered whether Manohar Chowdhry &amp; Associates&#8217; provision
of non-audit services to the Company was compatible with the auditor&#8217;s independence; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the review and discussion referred to above, and in reliance thereon, the Audit Committee recommended to the Board that the Audited
Financial Statements be included in the Company&#8217;s Annual Report on Form 10-K for Fiscal 2025, for filing with the U.S. Securities
and Exchange Commission.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
members of the Audit Committee concur in this report.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AUDIT
COMMITTEE:</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard
Prins</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
Moran</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 24; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; vertical-align: bottom; width: 0.4in"><img alt="" src="image_002.jpg"/></td><td style="text-align: left; vertical-align: bottom; width: 3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;|&#160;FYE2025 Form PRE 14A</span></td><td style="text-align: right; vertical-align: bottom"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROPOSALS
FOR 2026 ANNUAL MEETING</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the regulations of the SEC, if you desire to make a proposal to be acted upon at the 2026 Annual Meeting of Stockholders, you must deliver
the proposal, in proper form, to the Secretary of the Company, no later than April 27, 2026, in order for the proposal to be considered
for inclusion in the Company&#8217;s Proxy Statement and form of proxy for that meeting. Any stockholder proposals will be subject to
the requirements of the proxy rules adopted by the SEC. The address for the Secretary of the Company is 10224 Falls Road, Potomac, Maryland,
20854.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Bylaws also prescribe the procedure that a stockholder must follow to nominate directors or to bring other business before stockholders&#8217;
meetings. To nominate a candidate for director or to bring other business before a meeting, notice must be received by the Secretary
of the Company (i) no later than July 12, 2026 and no earlier than June 12, 2026, or (ii) if the date of the 2026 Annual Meeting of Stockholders
is advanced by more than thirty days or delayed by more than sixty days from the anniversary date of this Annual Meeting, no earlier
than the close of business on the later of the one hundred and twentieth day prior to such annual meeting or not later than the ninetieth
day prior to such annual meeting or the tenth day following the day on which public announcement of the date of such meeting is first
made by the Corporation and no earlier than the close of business on the ninetieth day prior to such Annual Meeting. In addition to the
requirements contained in our Bylaws, to comply with the universal proxy rules (when effective), stockholders who intend to solicit proxies
in support of director nominees other than our nominees must provide notice that sets forth the information required by Rule 14a-19 under
the Exchange Act no later than August 11, 2026 (the 60th day prior to the first anniversary of the annual meeting for the preceding year&#8217;s
annual meeting).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice
of a nomination for director must describe various matters regarding the nominee and the stockholder giving the notice. The notice of
other business to be brought before the Annual Meeting must include a description of the proposed business, the reasons therefore, and
other specified matters. The nominating committee will consider candidates recommended by stockholders in the same manner it considers
other candidates. Any stockholder may obtain a copy of the Company&#8217;s Bylaws, without charge, upon written request to the Secretary
of the Company, at the address set forth above.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANNUAL
REPORT</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of our Annual Report on Form 10-K for the fiscal year ended March 31, 2025, has been provided to all stockholders. Stockholders
refer to the report for financial and other information about us, but such a report is not incorporated in this proxy statement and is
not a part of the proxy soliciting material.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 25; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; vertical-align: bottom; width: 0.4in"><img alt="" src="image_002.jpg"/></td><td style="text-align: left; vertical-align: bottom; width: 3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;|&#160;FYE2025 Form PRE 14A</span></td><td style="text-align: right; vertical-align: bottom"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROXY
CARD</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THIS
PROXY IS SOLICITED ON BEHALF OF</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THE
BOARD OF DIRECTORS OF IGC PHARMA, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>for
the</b>&#160;<b>October 10, 2025, Annual Meeting of Stockholders and any postponement(s) or adjournment(s) thereof.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned hereby: (a) acknowledges receipt of the Notice of the Annual Stockholders&#8217; Meeting of IGC Pharma, Inc. to be held on
October 10, 2025, (the &#8220;Annual Meeting&#8221;), and the associated Proxy Statement; (b) appoint Mr. Ram Mukunda, as a proxy, with
the power to appoint a substitute; (c) authorizes each proxy to represent and vote, as designated below, all of the shares of common
stock of the Company, par value $0.0001 per share, held of record by the undersigned at the close of business on July 28, 2025, at the
Annual Meeting and at any postponement(s) or adjournment(s) thereof; and (d) revokes any proxies previously given.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPORTANT
NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON OCTOBER 10, 2025:</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>This
Proxy Statement, the Notice of Annual Meeting of Stockholders, and Our Annual Report to Stockholders are available at <span style="text-decoration:underline">http://www.igcpharma.com.</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    elect Mr. Ram Mukunda and Mr. James Moran to the Company&#8217;s Board of Directors to serve as Class C directors until the 2028
    Annual Meeting of Stockholders and until such director&#8217;s respective successor shall be duly elected and qualified, or until
    such director&#8217;s earlier death, resignation, or removal from office;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; width: 33%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MR. RAM MUKUNDA</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR </b>&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WITHHOLD </b>&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MR. JAMES MORAN</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR </b>&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WITHHOLD </b>&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    ratify the appointment of Manohar Chowdhry &amp; Associates, as the Company&#8217;s independent registered public accounting firm
    for the 2026 fiscal year;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR </b>&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AGAINST </b>&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABSTAIN </b>&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    approve the grant of 5,000,000 shares of common stock, governed by the Company&#8217;s 2018 Omnibus Incentive Plan, to be granted
    from time to time to the Company&#8217;s current and new employees, advisors, directors, and consultants by the Board of Directors,
    pursuant to certain metrics including performance, vesting, and incentive as set by the Board of Directors and or the CEO;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR </b>&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AGAINST </b>&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABSTAIN </b>&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt">4.</td>
    <td colspan="3" style="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To effect an amendment to our Amended and Restated Articles of Incorporation to increase the authorized number of shares of our common stock from 150,000,000 shares to 600,000,000 shares of common stock.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR </b>&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AGAINST </b>&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABSTAIN </b>&#9744;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt">5.</td>
    <td colspan="3" style="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To act upon such other matters as may properly come before the Annual Meeting, including any proposal to adjourn or postpone of the Annual Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies (the &#8220;Adjournment Proposal&#8221;).</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR </b>&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AGAINST </b>&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABSTAIN </b>&#9744;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>This
Proxy Card, when properly executed, will be voted in the manner directed herein by the undersigned stockholder(s). If no direction is
made, this Proxy will be voted FOR proposals set forth above. Please sign, date, and return this Proxy as promptly as possible in the
envelope provided.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:&#160;&#160;&#160;&#160;__________________,
    2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>X</b>&#160;________________________________</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>X</b>&#160;________________________________</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature(s)
    of Stockholders&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint
owners should each sign. Signature(s) should correspond with the name(s) printed on your stock certificates. Attorneys, executors, administrators,
and guardians should give full title. If a corporation, please sign in full corporate name by the president or other authorized officer.
If there is a partnership, please sign with the authorized person&#8217;s name in the partnership name.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 26; Options: Last --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" id="hidden-fact-0" name="dei:DocumentType">PRE 14A</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-4202">0001326205</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-4203">false</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="igc-20250805.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
<!-- [WMV6][nPdWaUHH9sCTjw8c2PzM0eUmQfVFEmLgRPPpl8Q0zsdeGjuW3FymXEtxC2QNhtHu1EcgXABdMJK1uDr7Xdy20ZpxOnmdNJvFySa10wzBmwIoroRy6zKiQgT3t0iafk7nVtU7loLFvg6mm6lHiQf+KinluHw1Cm/bNVUbVCpd7QLfHQSl57ZoK0+asK6uk4dZJ6h3TUoUAHXsN1yDMQR8+i4BckxjqaN1VXpKQgAy6agduuGQ7AC/4icO3Abvbwdal5BMi/TwiOrACBk8AN6OMgKBPoq/vIzyH42/Dpvp+knt8FvPYEitKdHxwjw9JjLF9GUBECd1Z6EzF7dB6wqHOM9dRiIA4MMQ] CSR-->
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">igc:EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">igc:EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">igc:EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">igc:EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">igc:EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">igc:EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:typedMember dimension="ecd:MeasureAxis">
        <ecd:MeasureAxis.domain>1</ecd:MeasureAxis.domain>
      </xbrldi:typedMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>2
<FILENAME>igc-20250805.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Sat Aug 02 17:02:56 UTC 2025 -->
<xs:schema elementFormDefault="qualified" targetNamespace="http://www.indiaglobalcap.com/20250805" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://xbrl.us/us-types/2009-01-31" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:igc="http://www.indiaglobalcap.com/20250805" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="igc-20250805_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="igc-20250805_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="igc-20250805_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/AdditionalDimensions" id="igc_r_AdditionalDimensions">
        <link:definition>999000 - Disclosure - Pay vs Performance Disclosure - Additional Dimensions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-sub-2025.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<!-- [WMV6][xDltPncS+XmWNlyfPkUERF2GqBdUgy4DRNLOsbldBC1cP/S9fHSAM/amuAVZQVB/TI0IfRIy0QiRLmeaDQ8xkuP/a6Ms5xrNVR9YIec6XoyA6i/AqnpNnP9i9CjF7XQQ4u2Bv/2I5n6wczdqNHLqw81KnLtOPwMAT8I9YVfvFP4IOCj+rIzoRvLAAojA8UoXtw5FWw3cznFG26cgu4oOF3Bpau2LuQOmvqf5pfHDEAk62c6HtkWn5nprH05+MLFqAyG4g0RFKf25gOv4X3KSYNgb6n+yC73BBBHcieLDeIMqLKYErmBCVnwHrs1c+f2spw6hR5rnqvEtlzMpqxTE1yCsG4d0wFZP] CSR-->
  <xs:element name="AllOtherCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="igc_AllOtherCompensation"/>
  <xs:element name="Bonus" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="igc_Bonus"/>
  <xs:element name="EquityAwards" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="igc_EquityAwards"/>
  <xs:element name="NonEquityIncentivePlanCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="igc_NonEquityIncentivePlanCompensation"/>
  <xs:element name="NonqualifiedDeferredCompensationEarnings" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="igc_NonqualifiedDeferredCompensationEarnings"/>
  <xs:element name="OptionAwards" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="igc_OptionAwards"/>
  <xs:element name="Pension" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="igc_Pension"/>
  <xs:element name="Salary" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="igc_Salary"/>
  <xs:element name="StockAwards" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="igc_StockAwards"/>
  <xs:element name="ChangeInPensionValueAndEquityAwardValueMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_ChangeInPensionValueAndEquityAwardValueMember"/>
  <xs:element name="EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember"/>
  <xs:element name="EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember"/>
  <xs:element name="EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember"/>
  <xs:element name="EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember"/>
  <xs:element name="EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember"/>
  <xs:element name="EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember"/>
  <xs:element name="EquityAwardsAdjustmentsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_EquityAwardsAdjustmentsMember"/>
  <xs:element name="EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember"/>
  <xs:element name="EquityAwardsValueInCompensationTableForTheApplicableYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_EquityAwardsValueInCompensationTableForTheApplicableYearMember"/>
  <xs:element name="NetAdjustmentsForEquityAwardsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_NetAdjustmentsForEquityAwardsMember"/>
  <xs:element name="NetAdjustmentsForPensionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_NetAdjustmentsForPensionMember"/>
  <xs:element name="PensionAdjustmentsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_PensionAdjustmentsMember"/>
  <xs:element name="PensionAdjustmentsPriorServiceCostMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_PensionAdjustmentsPriorServiceCostMember"/>
  <xs:element name="PensionAdjustmentsServiceCostMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_PensionAdjustmentsServiceCostMember"/>
  <xs:element name="PensionValueAndEquityAwardsValueInCompensationTableForTheApplicableYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_PensionValueAndEquityAwardsValueInCompensationTableForTheApplicableYearMember"/>
  <xs:element name="PensionValueInCompensationTableForTheApplicableYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_PensionValueInCompensationTableForTheApplicableYearMember"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>3
<FILENAME>igc-20250805_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Sat Aug 02 17:02:56 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250805.xsd#igc_r_AdditionalDimensions" roleURI="http://www.indiaglobalcap.com/role/AdditionalDimensions"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:type="extended">
<!-- [WMV6][+kBWpRJW9L58k6YF1+YDZwBfvHNReH7B4Dm6dV48Wf2FCNmh2sF+bhsasH8+X3ISUmE92mvdV+AXOP01GVyTP7JjY5RdHGY0psSOTY8aC0khXjh4UdIqg7QcLgDxdPNe6ymU7fMnjrLoBhblGLvQFLzl6Q0CAzYOOIu/aqpJvqsNwVeFjmxAsZCk6dBI/pfSBZAZPBq9Z8n1waZSZfMhCBs4yF1T+T0JMQss06VcwP3UKJK4xzkqsbWZYPt5Q1KKdylYcZtdvC9cwMkIp82G5oBojUonmbh7YTOsIF6RxS6opCaAP8Q45QBmLBHtsKoGneHOuoVC+NXk9p1pAje/KcnsXSOEBzAi] CSR-->
    <loc xlink:type="locator" xlink:label="ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <loc xlink:type="locator" xlink:label="igc_NetAdjustmentsForEquityAwardsMember" xlink:href="igc-20250805.xsd#igc_NetAdjustmentsForEquityAwardsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllAdjToCompMember" xlink:to="igc_NetAdjustmentsForEquityAwardsMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_EquityAwardsAdjustmentsMember" xlink:href="igc-20250805.xsd#igc_EquityAwardsAdjustmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_NetAdjustmentsForEquityAwardsMember" xlink:to="igc_EquityAwardsAdjustmentsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember" xlink:href="igc-20250805.xsd#igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_EquityAwardsAdjustmentsMember" xlink:to="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember" xlink:href="igc-20250805.xsd#igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember" xlink:to="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/AdditionalDimensions" xlink:type="extended"/>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>igc-20250805_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Sat Aug 02 17:02:56 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="igc_AllOtherCompensation" xlink:href="igc-20250805.xsd#igc_AllOtherCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_AllOtherCompensation_lbl" xml:lang="en-US">All Other Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_AllOtherCompensation" xlink:to="igc_AllOtherCompensation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_AllOtherCompensation_lbl0" xml:lang="en-US">All other compensation for the period that could not be properly reported in any other column of the Summary Compensation Table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_AllOtherCompensation" xlink:to="igc_AllOtherCompensation_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_Bonus" xlink:href="igc-20250805.xsd#igc_Bonus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_Bonus_lbl" xml:lang="en-US">Bonus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Bonus" xlink:to="igc_Bonus_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_Bonus_lbl0" xml:lang="en-US">The dollar value of bonus (cash and non-cash) earned by the named executive officer during the period as reported in the Summary Compensation Table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Bonus" xlink:to="igc_Bonus_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_EquityAwards" xlink:href="igc-20250805.xsd#igc_EquityAwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_EquityAwards_lbl" xml:lang="en-US">Equity Awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_EquityAwards" xlink:to="igc_EquityAwards_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_EquityAwards_lbl0" xml:lang="en-US">The aggregate grant date fair value computed in accordance with FASB ASC Topic 718 of all equity awards granted during the period as reported in the Summary Compensation Table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_EquityAwards" xlink:to="igc_EquityAwards_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_NonEquityIncentivePlanCompensation" xlink:href="igc-20250805.xsd#igc_NonEquityIncentivePlanCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_NonEquityIncentivePlanCompensation_lbl" xml:lang="en-US">Non-Equity Incentive Plan Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_NonEquityIncentivePlanCompensation" xlink:to="igc_NonEquityIncentivePlanCompensation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_NonEquityIncentivePlanCompensation_lbl0" xml:lang="en-US">The dollar value of (1) all earnings for services performed during the period pursuant to awards under non-equity incentive plans and (2) all earnings on any outstanding awards under such plans as reported in the Summary Compensation Table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_NonEquityIncentivePlanCompensation" xlink:to="igc_NonEquityIncentivePlanCompensation_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_NonqualifiedDeferredCompensationEarnings" xlink:href="igc-20250805.xsd#igc_NonqualifiedDeferredCompensationEarnings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_NonqualifiedDeferredCompensationEarnings_lbl" xml:lang="en-US">Nonqualified Deferred Compensation Earnings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_NonqualifiedDeferredCompensationEarnings" xlink:to="igc_NonqualifiedDeferredCompensationEarnings_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_NonqualifiedDeferredCompensationEarnings_lbl0" xml:lang="en-US">Above-market or preferential earnings on compensation that is deferred on a basis that is not tax-qualified, including any such earnings on nonqualified defined contribution plans, as reported in the Summary Compensation Table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_NonqualifiedDeferredCompensationEarnings" xlink:to="igc_NonqualifiedDeferredCompensationEarnings_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_OptionAwards" xlink:href="igc-20250805.xsd#igc_OptionAwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_OptionAwards_lbl" xml:lang="en-US">Option Awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_OptionAwards" xlink:to="igc_OptionAwards_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_OptionAwards_lbl0" xml:lang="en-US">The aggregate grant date fair value computed in accordance with FASB ASC Topic 718 for any awards of options, with or without tandem Stock Appreciation Rights (SARs), as reported in the Summary Compensation Table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_OptionAwards" xlink:to="igc_OptionAwards_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_Pension" xlink:href="igc-20250805.xsd#igc_Pension"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_Pension_lbl" xml:lang="en-US">Pension</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Pension" xlink:to="igc_Pension_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_Pension_lbl0" xml:lang="en-US">The aggregate pension value, as reported in the Summary Compensation Table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Pension" xlink:to="igc_Pension_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_Salary" xlink:href="igc-20250805.xsd#igc_Salary"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_Salary_lbl" xml:lang="en-US">Salary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Salary" xlink:to="igc_Salary_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_Salary_lbl0" xml:lang="en-US">The dollar value of base salary (cash and non-cash) earned by the named executive officer during the period as reported in the Summary Compensation Table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Salary" xlink:to="igc_Salary_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_StockAwards" xlink:href="igc-20250805.xsd#igc_StockAwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_StockAwards_lbl" xml:lang="en-US">Stock Awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_StockAwards" xlink:to="igc_StockAwards_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_StockAwards_lbl0" xml:lang="en-US">The aggregate grant date fair value computed in accordance with FASB ASC Topic 718 of all stock awards granted during the period as reported in the Summary Compensation Table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_StockAwards" xlink:to="igc_StockAwards_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_ChangeInPensionValueAndEquityAwardValueMember" xlink:href="igc-20250805.xsd#igc_ChangeInPensionValueAndEquityAwardValueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_ChangeInPensionValueAndEquityAwardValueMember_lbl" xml:lang="en-US">Change In Pension Value and Equity Award Value [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_ChangeInPensionValueAndEquityAwardValueMember" xlink:to="igc_ChangeInPensionValueAndEquityAwardValueMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_ChangeInPensionValueAndEquityAwardValueMember_lbl0" xml:lang="en-US">This member presents the total compensation adjustment for change in pension value and equity award value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_ChangeInPensionValueAndEquityAwardValueMember" xlink:to="igc_ChangeInPensionValueAndEquityAwardValueMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember" xlink:href="igc-20250805.xsd#igc_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember_lbl" xml:lang="en-US">Adjustments For Equity Awards Failed To Meet Performance Conditions [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember" xlink:to="igc_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember_lbl0" xml:lang="en-US">This member presents the equity awards adjustments on adjustments for equity awards that failed to meet performance conditions.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember" xlink:to="igc_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember" xlink:href="igc-20250805.xsd#igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember_lbl" xml:lang="en-US">Change In Fair Value As Of Vesting Date Of Current Year Awards Vested During Current Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember" xlink:to="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember_lbl0" xml:lang="en-US">This member presents the equity awards adjustments on the change in fair value (as of vesting date) of current  year awards vested during current year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember" xlink:to="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember" xlink:href="igc-20250805.xsd#igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember_lbl" xml:lang="en-US">Change In Fair Value As Of Vesting Date Of Prior Year Awards Vested During Current Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember" xlink:to="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember_lbl0" xml:lang="en-US">This member presents the equity awards adjustments on the change in fair value (as of vesting date) of prior year awards vested during current year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember" xlink:to="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember_lbl0"/>
<!-- [WMV6][5Q35l+dDb3cIDZjYNi6BBlJyVa172isCeXgtzhOt6FrohaczmI591mwhpNG7klLQZVbNjKW3/ens3LMKcjeRpymbHhp8YyauvgG6qarJwPKv7VoI3RUtNemWR9M2dXqd/9EjmA0rU4uN/shO0wfnci5UavbPZ+WqXPx6wVVb3/4io26iIidtQxTOV+UyM2npCTVN9Su4kjTMeFAFH+sXb5b0adhOgiBgSz41B01Aw6Zw8YxkYMFV1flwTKJ9OsWheke0oQGuh7Afs5b7O30gDxiceP/Q6mh+M4HSvI1/604wyFXNxNhMFhy2NDbDJh1ac7VakwQ2U5xhyuYQfG0N+CQgOhk1tQ==] CSR-->
    <loc xlink:type="locator" xlink:label="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember" xlink:href="igc-20250805.xsd#igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember_lbl" xml:lang="en-US">Change In Fair Value As Of Vesting Date Of Awards Vested During Current Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember" xlink:to="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember_lbl0" xml:lang="en-US">This member presents the equity awards adjustments on the change in fair value (as of vesting date) of awards vested during current year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember" xlink:to="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember" xlink:href="igc-20250805.xsd#igc_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember_lbl" xml:lang="en-US">Change In Fair Value Of Outstanding And Unvested Awards Granted In Prior Fiscal Years [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember" xlink:to="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember_lbl0" xml:lang="en-US">This member presents the equity awards adjustments on the change in fair value from the end of the prior fiscal year of any awards granted in prior years that are outstanding and unvested as of the end of the applicable year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember" xlink:to="igc_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember" xlink:href="igc-20250805.xsd#igc_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember_lbl" xml:lang="en-US">Dividends Or Other Earnings Paid On Equity Awards Not Otherwise Reflected In Fair Value [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember" xlink:to="igc_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember_lbl0" xml:lang="en-US">This member presents the equity awards adjustments on dividends or other earnings paid on equity awards not otherwise reflected in fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember" xlink:to="igc_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_EquityAwardsAdjustmentsMember" xlink:href="igc-20250805.xsd#igc_EquityAwardsAdjustmentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_EquityAwardsAdjustmentsMember_lbl" xml:lang="en-US">Total Equity Awards Adjustments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_EquityAwardsAdjustmentsMember" xlink:to="igc_EquityAwardsAdjustmentsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_EquityAwardsAdjustmentsMember_lbl0" xml:lang="en-US">This member presents the total equity awards adjustments, which may be comprised of adjustments for (i) the year-end fair value of any equity awards granted in the applicable year that are outstanding and unvested as of the end of the year; (ii) the change in fair value from the end of the prior fiscal year of any awards granted in prior years that are outstanding and unvested as of the end of the applicable year; (iii) for awards granted in prior years that vest in the applicable year, the amount equal to the change in value as of the vesting date (from the end of the prior fiscal year); (iv) adjustments for equity awards that failed to meet performance conditions; and (v) dividends or other earnings paid on equity awards not otherwise reflected in fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_EquityAwardsAdjustmentsMember" xlink:to="igc_EquityAwardsAdjustmentsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember" xlink:href="igc-20250805.xsd#igc_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember_lbl" xml:lang="en-US">Year-end Fair Value Of Awards Granted In The Current Fiscal Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember" xlink:to="igc_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember_lbl0" xml:lang="en-US">This member presents the equity awards adjustments on the year-end fair value of any equity awards granted in the applicable year that are outstanding and unvested as of the end of the year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember" xlink:to="igc_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_EquityAwardsValueInCompensationTableForTheApplicableYearMember" xlink:href="igc-20250805.xsd#igc_EquityAwardsValueInCompensationTableForTheApplicableYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_EquityAwardsValueInCompensationTableForTheApplicableYearMember_lbl" xml:lang="en-US">Equity Awards Value In Summary Compensation Table (Grant Date Value) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_EquityAwardsValueInCompensationTableForTheApplicableYearMember" xlink:to="igc_EquityAwardsValueInCompensationTableForTheApplicableYearMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_EquityAwardsValueInCompensationTableForTheApplicableYearMember_lbl0" xml:lang="en-US">This member presents the adjustment (deduction) for equity awards value from summary compensation table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_EquityAwardsValueInCompensationTableForTheApplicableYearMember" xlink:to="igc_EquityAwardsValueInCompensationTableForTheApplicableYearMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_NetAdjustmentsForEquityAwardsMember" xlink:href="igc-20250805.xsd#igc_NetAdjustmentsForEquityAwardsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_NetAdjustmentsForEquityAwardsMember_lbl" xml:lang="en-US">Total Net Adjustments For Equity Awards [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_NetAdjustmentsForEquityAwardsMember" xlink:to="igc_NetAdjustmentsForEquityAwardsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_NetAdjustmentsForEquityAwardsMember_lbl0" xml:lang="en-US">This member presents the net compensation adjustment for equity awards, which is comprised of equity awards value from summary compensation table, net of total equity awards adjustments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_NetAdjustmentsForEquityAwardsMember" xlink:to="igc_NetAdjustmentsForEquityAwardsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_NetAdjustmentsForPensionMember" xlink:href="igc-20250805.xsd#igc_NetAdjustmentsForPensionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_NetAdjustmentsForPensionMember_lbl" xml:lang="en-US">Total Net Adjustments For Pension [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_NetAdjustmentsForPensionMember" xlink:to="igc_NetAdjustmentsForPensionMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_NetAdjustmentsForPensionMember_lbl0" xml:lang="en-US">This member presents the net compensation adjustment for pension, which is comprised of pension value from summary compensation table, net of total pension adjustments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_NetAdjustmentsForPensionMember" xlink:to="igc_NetAdjustmentsForPensionMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_PensionAdjustmentsMember" xlink:href="igc-20250805.xsd#igc_PensionAdjustmentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_PensionAdjustmentsMember_lbl" xml:lang="en-US">Total Pension Adjustments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_PensionAdjustmentsMember" xlink:to="igc_PensionAdjustmentsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_PensionAdjustmentsMember_lbl0" xml:lang="en-US">This member presents the total pension adjustments, which may be comprised of adjustments for service cost and prior service cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_PensionAdjustmentsMember" xlink:to="igc_PensionAdjustmentsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_PensionAdjustmentsPriorServiceCostMember" xlink:href="igc-20250805.xsd#igc_PensionAdjustmentsPriorServiceCostMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_PensionAdjustmentsPriorServiceCostMember_lbl" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_PensionAdjustmentsPriorServiceCostMember" xlink:to="igc_PensionAdjustmentsPriorServiceCostMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_PensionAdjustmentsPriorServiceCostMember_lbl0" xml:lang="en-US">This member presents the total pension adjustments, prior service cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_PensionAdjustmentsPriorServiceCostMember" xlink:to="igc_PensionAdjustmentsPriorServiceCostMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_PensionAdjustmentsServiceCostMember" xlink:href="igc-20250805.xsd#igc_PensionAdjustmentsServiceCostMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_PensionAdjustmentsServiceCostMember_lbl" xml:lang="en-US">Pension Adjustments Service Cost [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_PensionAdjustmentsServiceCostMember" xlink:to="igc_PensionAdjustmentsServiceCostMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_PensionAdjustmentsServiceCostMember_lbl0" xml:lang="en-US">This member presents the pension adjustments, service cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_PensionAdjustmentsServiceCostMember" xlink:to="igc_PensionAdjustmentsServiceCostMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_PensionValueAndEquityAwardsValueInCompensationTableForTheApplicableYearMember" xlink:href="igc-20250805.xsd#igc_PensionValueAndEquityAwardsValueInCompensationTableForTheApplicableYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_PensionValueAndEquityAwardsValueInCompensationTableForTheApplicableYearMember_lbl" xml:lang="en-US">Pension Value And Equity Awards Value In Compensation Table For The Applicable Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_PensionValueAndEquityAwardsValueInCompensationTableForTheApplicableYearMember" xlink:to="igc_PensionValueAndEquityAwardsValueInCompensationTableForTheApplicableYearMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_PensionValueAndEquityAwardsValueInCompensationTableForTheApplicableYearMember_lbl0" xml:lang="en-US">This member presents the total compensation adjustment for pension value and equity awards value in compensation table for the applicable year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_PensionValueAndEquityAwardsValueInCompensationTableForTheApplicableYearMember" xlink:to="igc_PensionValueAndEquityAwardsValueInCompensationTableForTheApplicableYearMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_PensionValueInCompensationTableForTheApplicableYearMember" xlink:href="igc-20250805.xsd#igc_PensionValueInCompensationTableForTheApplicableYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_PensionValueInCompensationTableForTheApplicableYearMember_lbl" xml:lang="en-US">Pension Adjustments Pension Value In Summary Compensation Table [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_PensionValueInCompensationTableForTheApplicableYearMember" xlink:to="igc_PensionValueInCompensationTableForTheApplicableYearMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_PensionValueInCompensationTableForTheApplicableYearMember_lbl0" xml:lang="en-US">This member presents the adjustment (deduction) for pension value from summary compensation table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_PensionValueInCompensationTableForTheApplicableYearMember" xlink:to="igc_PensionValueInCompensationTableForTheApplicableYearMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_PensionAdjustmentsPriorServiceCostMember_lbl1" xml:lang="en-US">Pension Adjustments Prior Service Cost Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_PensionAdjustmentsPriorServiceCostMember" xlink:to="igc_PensionAdjustmentsPriorServiceCostMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_PensionAdjustmentsServiceCostMember_lbl1" xml:lang="en-US">Pension Adjustments Service Cost Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_PensionAdjustmentsServiceCostMember" xlink:to="igc_PensionAdjustmentsServiceCostMember_lbl1"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>igc-20250805_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Sat Aug 02 17:02:56 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure"/>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <loc xlink:type="locator" xlink:label="NetAdjustmentsForEquityAwardsMember" xlink:href="igc-20250805.xsd#igc_NetAdjustmentsForEquityAwardsMember"/>
<!-- [WMV6][PbJ2M8PmbPs+an8FEHGpI4PuZy9TPNx0jHT5VE9sgdbGrYsoiAZEC/ZoWET5zplQKFila0EqsuzVaHvs9VhhtlMkf6E6BV0jdpiowzwToXVlO9TSgS6QxGxhgSPqSO3oJYw1OPp2TJbyBTh9Xq8PcAo9a40oU88P+1ERWSuHe/e3ZCS/AQ12Gj1KDec3IkPf5IzBqI0VPk59c9gGWemW61LXqvfFmUaf1l5g5Bn9zgruyEoY2moyjR1ZTXg7vZqDCJS0McFNMRBNIY1ebyYQp5c2OU3zcw9ezM0tXMitoZAUiHe2j2/XO60A2PSPSZeSmShnotyEqNwgLq0JMICqwMlVw7YOiKmQcA==] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllAdjToCompMember" xlink:to="NetAdjustmentsForEquityAwardsMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="EquityAwardsAdjustmentsMember" xlink:href="igc-20250805.xsd#igc_EquityAwardsAdjustmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllAdjToCompMember" xlink:to="EquityAwardsAdjustmentsMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember" xlink:href="igc-20250805.xsd#igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllAdjToCompMember" xlink:to="EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember" xlink:href="igc-20250805.xsd#igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllAdjToCompMember" xlink:to="EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !  %<# 2(  A$! Q$!_\0
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MAC+PVC'[/)"6\DAB5DE$GY!Q3)XSB"5#GE*E&I1C&GU5HQO[JLEJV_G?S/\
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MY8IR?):"ORGQE:4,/&4Y33C5Y>5I[-JSNWLN;5VTMOL?RK_M._LV_P#!OO\
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MASX<:'X1TOQ%</JTLOEM]JUO3;2\TS3-/1I%\W4=4CBLX8PS,&(.SV[X0_\
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M<?M@Z'<JJ-<0?#OQ1J=@6.6TV_>2WTY[1"<B;R(TG(:=968719B2D13^P/\
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M7W2%%#DE174^'=#L-"TRVTJP@"6-G&L5LC(,",9POS;F.WCYF);DC<>:YJ6
MC3I5:3J27[V-2A*-DX6U;DG;5N^BNNFQZ'&/%=/BRK#&5,.Z.-DG&O*T>24+
M*,8J2]Z5DDTY)--/?F9^!G_!6[_@@K\"O^"D#W?Q0\'7Q^"7[4>G:5(UA\2-
M(TZWF\.^-9 MLT.D^.M%C>WBU9D:U$-KK@C%[IPU"^EN9+C[5$(O\_O]LO\
MX)Q_MN_\$^/%S6OQU^%OBGPG:Z%J?]JZ'\8/ $=WXH\ R16,]HT7B'2_$NEV
M33V=W9/<6-QJ%C=-;OIPN4C1Y@\P3_8/EAC8IO1&C7=E652-QQM(!X&.>G^%
M<QXN\(>%/&F@7WAWQEH&C^)]#U!1%J.B^(+&'5-(OX9-R>1>V-Y'-:RP,K,I
M26)H\X)4G::_?/#_ ,=>,>#,-'),;BI9]PLJ:P\<EQ7+%T,/*-JD*.(E&<FF
M[N,)OEBI64HI(_,\5E.'K.,Z?N54[MOX9-;;:KS/X7_^"1?_  52;]H#1-.\
M&^(O%UIX4_:G^&.BQPI<VMU%%H_QJ\+:4L4-IXA2U%[ KZXUN0NI(M@DTKSP
M%MS!J_L'_9S_ &FM%^,T!\/:\D&A?$33$2.\T&23;+J\-M#YGV^.&>&/R#.7
M8JBNX8JY0JJ[3^<'[0W_  ;P?\$W_C=XB3QQX3^'/B#]G3XGVU_#J>F>/?@=
MXDOO">H:9J D:6":VLX;Q].DMT<2,]B;46<P=DFMY$6()ZW\(_\ @FU\2_A/
MJ?AI]3_:BUOQ]!X1NH3IGB;Q+X?M[/Q[+80E/+LK^\T1+73=1#(D:.YLP^%)
MD,QD^7P^/<WX%XIJULSR;+<5D]?$N-2>6UH\V&HS22FX55*3J1J3YJDDK6<K
M*VC.RA3Q-&,8.5.5..BO)MN^CT<=#]>( LB^88I"6R-LX :(@D&,QA0B;<XS
MC<PQN9MH:K*QHG**$.03LRN2 0 =I&X#)X.1[4VP0BUMUDE:XDCMX(Y+B12D
MT[QIL>>5#C:TS*9-N!@L<#&*M^6G7'U]\XZ_E^IK\F>&H)M4\/2IQO[LH-\R
M?=*R7S;;:WU.V\7O'7K;;\T,C5=S-CYCC)YY/()QTR>YQD]Z*D50N<#&>316
7T(\D5'F<K7UE:[N[ZVTTO8EVOIL?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  < "\# 2(  A$! Q$!_\0
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M7[0O@OX-^/=2TGPC^Q_^P+^RYK&F>!Q?:%_;OA__ (2[XU_&SQ^?!WQS^/\
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MD\=GR!^3/[8W_!*WX%>+/ WB#54^(GQE\/']IGXV?'[X'_'33M-?X,Z[I'Q
M^&7Q\_;=^)G[4DNAW&G^/_@QXTA\.ZI\(?C3XM\0^*_@AXV\&_\ ".>//!4V
MI3)?^)_$3[9E^G;+]B#1-1_: _:0_90M_CY\?-*_99^.'A3XT_'GQU\ +<_
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M-7US0O$GAJ+Q#HWB;X6_$70=9\*^-?A@8X_C);^,M#EC7P:K*PF]8\,?M0_
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:F]+U8.7NW2;23Y6US^VMNNMKKU:?7RT/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">PRE 14A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IGC
Pharma, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001326205<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTableTextBlock', window );">Pay vs Performance Disclosure, Table</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pay
Versus Performance Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(in
thousands)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included
in the table below is the annual compensation paid to our executives and our financial performance for each of the three previous years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Summary<br/> Compensation <br/>
Table <br/>
Total for <br/>
PEO(1)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Compensation <br/>
Actually <br/>
Paid to <br/>
PEO(3)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Average <br/>
Summary <br/>
Compensation <br/>
Table <br/>
Total for <br/>
Non-PEO <br/>
NEOs <br/>
Officer(2)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Average <br/>
Compensation <br/>
Actually <br/>
Paid to <br/>
Non-PEO <br/>
NEOs(3)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Value of <br/>
Initial <br/>
Fixed $100 <br/>
Investment <br/>
Based On: <br/>
Total <br/>
Shareholder <br/>
Return(4)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Net Income <br/>
(Loss)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">(a)</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">(b)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">(c)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">(d)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">(e)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">(f)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">(g)</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%; text-align: center; padding-left: 0.25pt">2025</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">568</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(203</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">259</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">78</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">70</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(7,121</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: center; padding-left: 0.25pt">2024</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">1,821</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">2,699</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">717</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">979</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">118</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(13,000</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-left: 0.25pt">2023</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">1,006</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(1,453</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">320</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">103</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(11,927</td><td style="text-align: left">)</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
fiscal years 2025, 2024, and 2023, this is the total compensation, as disclosed in the Summary Compensation Table above, for Mr. Ram
Mukunda, our Principal Executive Officer (&#8220;PEO&#8221;).</span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
fiscal years 2025, 2024, and 2023, this is the total compensation, as disclosed in the Summary Compensation Table above, for Ms. Claudia
Grimaldi, our non-PEO NEO.</span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
Actually Paid is the Summary Compensation Table total for the PEO (column (b) above) and Summary Compensation Table total for the Non-PEO
(column (d) above), as applicable, with the adjustments pursuant to Item 402(v)(2)(iii)(C) of Regulations S-K.</span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The&#160;Total
Shareholder Return reflected in this column for each applicable fiscal year is calculated based on a fixed investment of $100 through
the end of the applicable fiscal year on the same cumulative basis.</span></td>
</tr></table><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">FYE 2025</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">FYE 2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">FYE 2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">FYE 2025</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">FYE 2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">FYE 2023</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">PEO</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">PEO</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">PEO</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-PEO</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-PEO</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-PEO</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; width: 28%; font-weight: bold; text-align: left; padding-left: 0.125in">SCT Total Compensation</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">568</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,821</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,006</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">259</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">717</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">320</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Subtract: Grant date fair value of equity awards granted during the covered year</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(1,066</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(301</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(370</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(75</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Add: Fair value as of the end of the covered fiscal year of all awards granted during the covered fiscal year that were outstanding and unvested as of the end of the fiscal covered year;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,517</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">159</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">535</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">40</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Add: Change in fair value from the end of the prior fiscal year to the end of the covered fiscal year for awards granted in any prior fiscal year that were outstanding and unvested as of the end of the covered fiscal year</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(663</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">158</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(1,804</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(148</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(129</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Add: Fair value as of the vesting date of awards that were granted and vested in the same year</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">234</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">79</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">78</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Add: Change in fair value from the end of the prior fiscal year to the vesting date of awards granted in any prior fiscal year that vested in the covered fiscal year</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(108</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">34</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(592</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(33</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(72</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Subtract: Fair value at the end of the prior fiscal year of awards granted in any prior fiscal year that failed to vest (forfeited) in the covered fiscal year</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Add: Dollar amount of dividends or other earnings paid on equity awards in the covered fiscal year prior to the vesting date that are not included in total compensation for the covered fiscal year</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; font-weight: bold; text-align: left; padding-left: 0.125in">Compensation Actually Paid</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(203</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">2,699</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(1,453</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">78</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">979</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">103</td><td style="font-weight: bold; text-align: left">&#160;</td></tr> </table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NamedExecutiveOfficersFnTextBlock', window );">Named Executive Officers, Footnote</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
fiscal years 2025, 2024, and 2023, this is the total compensation, as disclosed in the Summary Compensation Table above, for Mr. Ram
Mukunda, our Principal Executive Officer (&#8220;PEO&#8221;).</span></td>
</tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
fiscal years 2025, 2024, and 2023, this is the total compensation, as disclosed in the Summary Compensation Table above, for Ms. Claudia
Grimaldi, our non-PEO NEO.</span></td>
</tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoTotalCompAmt', window );">PEO Total Compensation Amount</a></td>
<td class="nump">$ 568<span></span>
</td>
<td class="nump">$ 1,821<span></span>
</td>
<td class="nump">$ 1,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoActuallyPaidCompAmt', window );">PEO Actually Paid Compensation Amount</a></td>
<td class="num">$ (203)<span></span>
</td>
<td class="nump">2,699<span></span>
</td>
<td class="num">(1,453)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToPeoCompFnTextBlock', window );">Adjustment To PEO Compensation, Footnote</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">FYE 2025</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">FYE 2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">FYE 2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">FYE 2025</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">FYE 2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">FYE 2023</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">PEO</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">PEO</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">PEO</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-PEO</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-PEO</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-PEO</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; width: 28%; font-weight: bold; text-align: left; padding-left: 0.125in">SCT Total Compensation</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">568</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,821</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,006</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">259</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">717</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">320</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Subtract: Grant date fair value of equity awards granted during the covered year</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(1,066</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(301</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(370</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(75</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Add: Fair value as of the end of the covered fiscal year of all awards granted during the covered fiscal year that were outstanding and unvested as of the end of the fiscal covered year;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,517</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">159</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">535</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">40</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Add: Change in fair value from the end of the prior fiscal year to the end of the covered fiscal year for awards granted in any prior fiscal year that were outstanding and unvested as of the end of the covered fiscal year</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(663</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">158</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(1,804</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(148</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(129</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Add: Fair value as of the vesting date of awards that were granted and vested in the same year</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">234</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">79</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">78</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Add: Change in fair value from the end of the prior fiscal year to the vesting date of awards granted in any prior fiscal year that vested in the covered fiscal year</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(108</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">34</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(592</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(33</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(72</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Subtract: Fair value at the end of the prior fiscal year of awards granted in any prior fiscal year that failed to vest (forfeited) in the covered fiscal year</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Add: Dollar amount of dividends or other earnings paid on equity awards in the covered fiscal year prior to the vesting date that are not included in total compensation for the covered fiscal year</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; font-weight: bold; text-align: left; padding-left: 0.125in">Compensation Actually Paid</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(203</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">2,699</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(1,453</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">78</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">979</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">103</td><td style="font-weight: bold; text-align: left">&#160;</td></tr> </table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgTotalCompAmt', window );">Non-PEO NEO Average Total Compensation Amount</a></td>
<td class="nump">$ 259<span></span>
</td>
<td class="nump">717<span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgCompActuallyPaidAmt', window );">Non-PEO NEO Average Compensation Actually Paid Amount</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">979<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToNonPeoNeoCompFnTextBlock', window );">Adjustment to Non-PEO NEO Compensation Footnote</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">FYE 2025</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">FYE 2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">FYE 2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">FYE 2025</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">FYE 2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">FYE 2023</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">PEO</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">PEO</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">PEO</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-PEO</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-PEO</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-PEO</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; width: 28%; font-weight: bold; text-align: left; padding-left: 0.125in">SCT Total Compensation</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">568</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,821</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,006</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">259</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">717</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">320</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Subtract: Grant date fair value of equity awards granted during the covered year</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(1,066</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(301</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(370</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(75</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Add: Fair value as of the end of the covered fiscal year of all awards granted during the covered fiscal year that were outstanding and unvested as of the end of the fiscal covered year;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,517</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">159</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">535</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">40</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Add: Change in fair value from the end of the prior fiscal year to the end of the covered fiscal year for awards granted in any prior fiscal year that were outstanding and unvested as of the end of the covered fiscal year</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(663</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">158</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(1,804</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(148</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(129</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Add: Fair value as of the vesting date of awards that were granted and vested in the same year</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">234</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">79</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">78</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Add: Change in fair value from the end of the prior fiscal year to the vesting date of awards granted in any prior fiscal year that vested in the covered fiscal year</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(108</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">34</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(592</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(33</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(72</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Subtract: Fair value at the end of the prior fiscal year of awards granted in any prior fiscal year that failed to vest (forfeited) in the covered fiscal year</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Add: Dollar amount of dividends or other earnings paid on equity awards in the covered fiscal year prior to the vesting date that are not included in total compensation for the covered fiscal year</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; font-weight: bold; text-align: left; padding-left: 0.125in">Compensation Actually Paid</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(203</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">2,699</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(1,453</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">78</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">979</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">103</td><td style="font-weight: bold; text-align: left">&#160;</td></tr> </table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock', window );">Compensation Actually Paid vs. Total Shareholder Return</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Relationship
Between Compensation Actually Paid and Company Total Shareholder Return</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Part
of the overall compensation is the stock price. In fiscal years 2025 and 2024, the metrics set by the Compensation Committee and the
Board with respect to stock price were not met. The PEO and non-PEO were therefore compensated based on shareholder return or value of
stock during the fiscal year in each of the 2025 and 2024 fiscal years in the form of stock awards based on market-based milestones.
These stock milestones are described under the Narrative to Summary Compensation Table section of this Proxy Statement.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TotalShareholderRtnAmt', window );">Total Shareholder Return Amount</a></td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (7,121)<span></span>
</td>
<td class="num">$ (13,000)<span></span>
</td>
<td class="num">$ (11,927)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoName', window );">PEO Name</a></td>
<td class="text">Mr. Ram
Mukunda<span></span>
</td>
<td class="text">Mr. Ram
Mukunda<span></span>
</td>
<td class="text">Mr. Ram
Mukunda<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Additional402vDisclosureTextBlock', window );">Additional 402(v) Disclosure</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
Actually Paid is the Summary Compensation Table total for the PEO (column (b) above) and Summary Compensation Table total for the Non-PEO
(column (d) above), as applicable, with the adjustments pursuant to Item 402(v)(2)(iii)(C) of Regulations S-K.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MeasureAxis=1', window );">Measure:: 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_CompActuallyPaidVsOtherMeasureTextBlock', window );">Compensation Actually Paid vs. Other Measure</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Relationship
Between Compensation Actually Paid and Operational Milestones</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not look to net income (loss) as a performance measure for its executive compensation program and instead looks at operational
metrics, such as drug development milestones, pipeline progress, R&amp;D spend, regulatory compliance, intellectual property, partnerships,
collaborations, and general financial health of the Company. The compensation actually paid for both our PEO and non-PEO NEO decreased
between the 2024 fiscal year and Fiscal 2025. This is primarily because the compensation is structured with stock, and the stock did
not perform well despite meeting operational milestones.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation actually paid to our named executive officers from Fiscal 2025 versus the 2024 fiscal year generally reflects cash bonuses
and stock awards, some of which vest based on milestones and others based on time. In addition, the Company decreased operating loss
reflecting a diligent commitment to the financial health of the Company.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1,066)<span></span>
</td>
<td class="num">$ (301)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,517<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="num">(663)<span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="num">(1,804)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">234<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO | Change In Fair Value As Of Vesting Date Of Prior Year Awards Vested During Current Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="num">(108)<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="num">(592)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(370)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">535<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="num">(148)<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="num">(129)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO | Change In Fair Value As Of Vesting Date Of Prior Year Awards Vested During Current Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="num">$ (33)<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="num">$ (72)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Additional402vDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Additional402vDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToNonPeoNeoCompFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToNonPeoNeoCompFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToPeoCompFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToPeoCompFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_CompActuallyPaidVsOtherMeasureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 5<br> -Subparagraph iv<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_CompActuallyPaidVsOtherMeasureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 5<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NamedExecutiveOfficersFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NamedExecutiveOfficersFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonPeoNeoAvgCompActuallyPaidAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonPeoNeoAvgCompActuallyPaidAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonPeoNeoAvgTotalCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonPeoNeoAvgTotalCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoActuallyPaidCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoActuallyPaidCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoTotalCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoTotalCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TotalShareholderRtnAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iv<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TotalShareholderRtnAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MeasureAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MeasureAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_ExecutiveCategoryAxis=ecd_PeoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Award Timing Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgDiscLineItems', window );"><strong>Award Timing Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiDiscTextBlock', window );">Award Timing MNPI Disclosure</a></td>
<td class="text">Neither
the Board nor the Compensation Committee takes material nonpublic information into account when determining the timing or terms of equity
awards, including with respect to options, nor do we time the disclosure of material nonpublic information for the purpose of affecting
the value of executive compensation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMethodTextBlock', window );">Award Timing Method</a></td>
<td class="text">we
have generally granted such awards once a year to directors and executive officers, and equity awards may be granted at other times during
the year to newly hired or promoted employees, and in other special circumstances.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiCnsdrdFlag', window );">Award Timing MNPI Considered</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgHowMnpiCnsdrdTextBlock', window );">Award Timing, How MNPI Considered</a></td>
<td class="text">we do not have a formal policy with respect to the timing of our equity award grants, we
have generally granted such awards once a year to directors and executive officers, and equity awards may be granted at other times during
the year to newly hired or promoted employees, and in other special circumstances. In fiscal 2025, we did not grant any stock options,
stock appreciation rights, or similar option-like instruments.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MnpiDiscTimedForCompValFlag', window );">MNPI Disclosure Timed for Compensation Value</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgDiscLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgDiscLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgHowMnpiCnsdrdTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgHowMnpiCnsdrdTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMethodTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMethodTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiCnsdrdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiCnsdrdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiDiscTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiDiscTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MnpiDiscTimedForCompValFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MnpiDiscTimedForCompValFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>46</ContextCount>
  <ElementCount>25</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>10</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>1</UnitCount>
  <MyReports>
    <Report instance="igcpre14a080225.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="igcpre14a080225.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="igcpre14a080225.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995443 - Disclosure - Award Timing Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure</Role>
      <ShortName>Award Timing Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="igcpre14a080225.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>igc-20250805.xsd</File>
    <File>igc-20250805_def.xml</File>
    <File>igc-20250805_lab.xml</File>
    <File>igc-20250805_pre.xml</File>
    <File doctype="PRE 14A" isUsgaap="true" original="igcpre14a080225.htm">igcpre14a080225.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="3">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="85">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "igcpre14a080225.htm": {
   "nsprefix": "igc",
   "nsuri": "http://www.indiaglobalcap.com/20250805",
   "dts": {
    "schema": {
     "local": [
      "igc-20250805.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025_def.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025_lab.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025_pre.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-sub-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "igc-20250805_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "igc-20250805_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "igc-20250805_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "igcpre14a080225.htm"
     ]
    }
   },
   "keyStandard": 25,
   "keyCustom": 0,
   "axisStandard": 3,
   "axisCustom": 0,
   "memberStandard": 9,
   "memberCustom": 1,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 46,
   "entityCount": 1,
   "segmentCount": 10,
   "elementCount": 270,
   "unitCount": 1,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ecd/2025": 85,
    "http://xbrl.sec.gov/dei/2025": 4,
    "http://fasb.org/us-gaap/2025": 3
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igcpre14a080225.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igcpre14a080225.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ecd:PvpTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igcpre14a080225.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ecd:PvpTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igcpre14a080225.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
     "longName": "995443 - Disclosure - Award Timing Disclosure",
     "shortName": "Award Timing Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igcpre14a080225.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igcpre14a080225.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igcpre14a080225.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igcpre14a080225.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r94",
      "r105",
      "r121",
      "r156"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r97",
      "r108",
      "r124",
      "r159"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r98",
      "r109",
      "r125",
      "r151",
      "r160",
      "r164",
      "r172"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r89",
      "r101"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r89",
      "r101"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r89",
      "r101"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52",
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r89",
      "r101"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114",
      "r128"
     ]
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114",
      "r128"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r89",
      "r101"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r89",
      "r101",
      "r152"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r89",
      "r101",
      "r152"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221"
     ]
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250805",
     "localname": "EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change In Fair Value As Of Vesting Date Of Prior Year Awards Vested During Current Year [Member]",
        "documentation": "This member presents the equity awards adjustments on the change in fair value (as of vesting date) of prior year awards vested during current year."
       }
      }
     },
     "auth_ref": []
    },
    "igc_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250805",
     "localname": "EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change In Fair Value As Of Vesting Date Of Awards Vested During Current Year [Member]",
        "documentation": "This member presents the equity awards adjustments on the change in fair value (as of vesting date) of awards vested during current year."
       }
      }
     },
     "auth_ref": []
    },
    "igc_EquityAwardsAdjustmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250805",
     "localname": "EquityAwardsAdjustmentsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Equity Awards Adjustments [Member]",
        "documentation": "This member presents the total equity awards adjustments, which may be comprised of adjustments for (i) the year-end fair value of any equity awards granted in the applicable year that are outstanding and unvested as of the end of the year; (ii) the change in fair value from the end of the prior fiscal year of any awards granted in prior years that are outstanding and unvested as of the end of the applicable year; (iii) for awards granted in prior years that vest in the applicable year, the amount equal to the change in value as of the vesting date (from the end of the prior fiscal year); (iv) adjustments for equity awards that failed to meet performance conditions; and (v) dividends or other earnings paid on equity awards not otherwise reflected in fair value."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r94",
      "r105",
      "r121",
      "r156"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r91",
      "r102",
      "r118",
      "r153"
     ]
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r98",
      "r109",
      "r125",
      "r160"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r98",
      "r109",
      "r125",
      "r160"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r98",
      "r109",
      "r125",
      "r160"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r98",
      "r109",
      "r125",
      "r160"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r98",
      "r109",
      "r125",
      "r160"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r88",
      "r112"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r89",
      "r101"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r98",
      "r109",
      "r125",
      "r151",
      "r160",
      "r164",
      "r172"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r90",
      "r176"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r90",
      "r176"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r90",
      "r176"
     ]
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r117"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "igc_NetAdjustmentsForEquityAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250805",
     "localname": "NetAdjustmentsForEquityAwardsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Net Adjustments For Equity Awards [Member]",
        "documentation": "This member presents the net compensation adjustment for equity awards, which is comprised of equity awards value from summary compensation table, net of total equity awards adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r61",
      "r62",
      "r63",
      "r64",
      "r65",
      "r66",
      "r67",
      "r68",
      "r69",
      "r70",
      "r71",
      "r72",
      "r73",
      "r195"
     ]
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r117"
     ]
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r98",
      "r109",
      "r125",
      "r151",
      "r160"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r96",
      "r107",
      "r123",
      "r158"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r99",
      "r110",
      "r126",
      "r161"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r99",
      "r110",
      "r126",
      "r161"
     ]
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r91",
      "r102",
      "r118",
      "r153"
     ]
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r92",
      "r103",
      "r119",
      "r154"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r93",
      "r104",
      "r120",
      "r155"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r100",
      "r111",
      "r127",
      "r162"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52",
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r95",
      "r106",
      "r122",
      "r157"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001185185-25-000890-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001185185-25-000890-xbrl.zip
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MN;XTDSRZ^5NKYX,7] 5>5"7#WSR!__=K$16Q^DW\^HK_XGF_3E4A19 FA4J
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MM@%UT;\18IO/@3)Q@?]YU_'?=M[YW6YO18:-EY9%7@#GX)(A.*"_TDP#YN'
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M<%":]M??^[X^?NW;%6-"OJ@>T9BA)>ZM^&AP!MC3T,#D:()@V:'+@-W-(%"
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M%+MEOC1K%#ZDR"SXQ\FH5]:.US)/$FQ<#MO ECS"ESM&.N5F5<9X;?*GY"S
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MBQ\M)%>+T,M\BJM64XE6D]UIFD'S@-06OB%<89=&0['@':KFA8K5"ZT1PK6
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M6<A!9<J5J+NJ$K?8\[-N7JIIE\\Y:.4!.6CTW8QS'9, %Z/?/% &2O9N@-D
M28_C#<R9G!G$R3$Q-M=P#N$YLL)M*U?AUO3C*"F>W4 ?"D53:5%<&%2(E0^_
M.UCTT'TR?]BMUDSEEN7@]59_8%K_:[7J0?(:E<&@P+>F[^%A4HHVAI^G_5&W
M&Q0$2(N2<9FJ?"2%D5"3'ZO9<<2#"N5(HUD 2%@NP<.*#2<<\B!K )S4/U_6
MS1O,!S"JL&Z':B&9]UC.\8-9I7)SV$:U%;N4N1183BB#S)*RZS_LX00NCO@
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MD]K!W.(OYQD.)@M <./=.8/HJ+8LD5M[NU/&82SB\FBE0N8='W6TNR0',6T
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M=X&:!3W*1CZ$ $;2($G:QE'0!.B$4=+!P@]%7N.G;?O4:YI-Z%I/73P)ZYL
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MQ+?:RR#<=]W6 %M!9 7P7@&$']I3H^V^[)FXZF@[=\@24#44GA3 !QO'!VM
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MC4@#:5U:LJU9L#/+%E)]PX(!40F.T3^"OH92YLH-.!4;;B5N"\AGZ&!;#FX
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M-;8=&_]&Y%.S3#")I>X)WN0(B]NKX*S$5*[07&&SD<-F;#^=I0+4QKI292)
M=Q1^%U;@.ND3GDB>*"4-DAT>V9;%$R8D:H9#O0G1;$:KI2@XFB;J.$'T!.,]
M$<"!Y%E/^6="Y[MZ)+&!8[H5NK+P[J:+<<+<0DK:O@PY(= T[""$;R2PEK9
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M* Z@G&?5LF7Q3.P5GHG",[%ZGHF]PC.Q! 1F=024F]OK/_XT3NJWIX4+8F%
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MN:4GS%-V*JL37)*'\\QI;0]^)&@2]*^V/5I@0[C^8XD4)PG $, BR/F'UAH
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M<\M!1(Q%/;QN?>5N9PC(Z]8- "_X4U@!OXN_"?LT#N"!$^[3AC^^D6#'I6/
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MF-7PZ>I9AD&>5\T4+UN3BESAT:N=]H[AFNP)R),"D^!1/_^]M;4NG@+M:[K
M"7:I))]O.6PRE+<]>[*CW?>8D'%64[?I"H@\J>2[. 'CPG5VOX*X="\_/XG-
M@3_Y;"D+*^=[ZGI?]'DS@9%6$F<7@ *XW.^S-?W#^LO *;T O$Z.43OE)=7;
MG[U#NZL0JJ%@[R[1Z3+B>@99.\KO8XP:R3 BIA46F(3Y;B Z#WK<,"P[L/"P
M:<KE>>:R SV_I2Z9Y2PYAN[26>H%('XEQA%1,NC< AP29HV;Y.ZHXX="N^6=
M$>N)*"&6=/%\AEC<5")!0-S?;G='=BL18VPF&.[B[]69O=T6>0&P&HD1'KZ9
MX6 !V[*)XQ]IY(W"/_=3^5R#;PQ*<\R]HBQ8Y+#BV%416W&"Q?$"N>3X/-F.
MNT>5M]85(;EEN<O-G1%=L,+OX/*VOO74;@"IBQ89C17F\%F3;B:L5?SE;HNH
M:#*MMO-3H,VRIT::O9?[D#Q\C+".S"Q0X*-NK[=*HE8"W++9N/82R_*ZNKXK
M9OU4-FZBA!GM?O#Z&@M)C% P^5>>.=+>.)X/81)\N&%-!";72Y@OJO])5HG.
MS]HVGP\3@&K85G?"_!*@HV^*K53,?KGKCZV]RV=JHRD7B5HMAK^"Z8\S";H_
MQ6ZA;PW<5&',%4NJ47\7^<@H9Q>X#Z1>K11'PB<^&78'6-7#)S>!<5:(G_#1
MO]__+J.M&STAKNPA6:P/78PVZIW?-R_/7CO!UI5+3DJ;19AZU5?;ATF>1VIB
ML?48:PN2]:D:R1A;DJ"2FGYWT%D0I;?P(KOB(/"F$^W,C/ZBN^?+Q&CS %D1
MY)NO%:-F[LQY=*0>KY9T%P,NS"0#?*^E759W(.11OH+^,9.[1$+5 GYW;6^"
MOY&MLD>7,<N__COK.8LDD;O\X_E\"1U9X7J>/2LK67+^,R!",M[$VBJ9]DVV
MWZ=GK6%OD\8VM7]BWI&3SS(U^*!I)2TEO="D/VQG99-_!A<P"PBF0#;#BN^J
M60YC%-[OQ1,5"1B%4]#;O$,#5RM#G9*W00]A2LD2VC#S2OX<-_Y8RW*!T]H1
MW^63]?$+@.LY9,F)H_\"4'Z$=Q"ZHMQ\Y9G">\0S+4C(L9&E&V^-X9UHNU <
M?04&@LB;O  L:I+96(^%$&<P#=I^8OY0'@-PB#4]K[6@&ZY\RY.5F:0G58DB
M7 "2E-=O184W<MQ===*G%,E<D @Z;+T K/'>M[SN3JE'I:0$0 +8![!N;^D
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MQ+J83/E/MPM$RU[L&98V.?Y!VA"GJ/^D4OJX K+0V[>IL2P8<O4;1[-,%@5
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MS"A+^<_V.G GFHHL+4^A5U;CHFL?IVOIJ*]Z#QAT$W1 1Z%I,U2HY%9VV&&
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M9V,M,C R-3 X,#4N>'-D4$L! A0#%     @ 23 $6V#XM!QK!   +!$  !0
M             ( !\ 8  &EG8RTR,#(U,#@P-5]D968N>&UL4$L! A0#%
M  @ 23 $6[3SK9KF#   T84  !0              ( !C0L  &EG8RTR,#(U
M,#@P-5]L86(N>&UL4$L! A0#%     @ 23 $6X:T^PG2 P  L@P  !0
M         ( !I1@  &EG8RTR,#(U,#@P-5]P<F4N>&UL4$L! A0#%     @
M23 $6[?%&FS*L0  JN\% !,              ( !J1P  &EG8W!R93$T83 X
M,#(R-2YH=&U02P$"% ,4    " !), 1;W>9SXZD7  "&&   #0
M    @ &DS@  :6UA9V5?,# Q+FIP9U!+ 0(4 Q0    ( $DP!%M.W/CC3 D
M $P*   -              "  7CF  !I;6%G95\P,#(N:G!G4$L%!@     '
-  < NP$  ._O      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>igcpre14a080225_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:igc="http://www.indiaglobalcap.com/20250805"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="igc-20250805.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">igc:EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">igc:EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">igc:EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">igc:EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">igc:EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">igc:EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:typedMember dimension="ecd:MeasureAxis">
                    <ecd:MeasureAxis.domain>1</ecd:MeasureAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-139">IGC Pharma, Inc.</dei:EntityRegistrantName>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c0" id="ixv-4118">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <ecd:AwardTmgMnpiDiscTextBlock contextRef="c0" id="ixv-4119">Neither
the Board nor the Compensation Committee takes material nonpublic information into account when determining the timing or terms of equity
awards, including with respect to options, nor do we time the disclosure of material nonpublic information for the purpose of affecting
the value of executive compensation.</ecd:AwardTmgMnpiDiscTextBlock>
    <ecd:AwardTmgHowMnpiCnsdrdTextBlock contextRef="c0" id="ixv-4120">we do not have a formal policy with respect to the timing of our equity award grants, we
have generally granted such awards once a year to directors and executive officers, and equity awards may be granted at other times during
the year to newly hired or promoted employees, and in other special circumstances. In fiscal 2025, we did not grant any stock options,
stock appreciation rights, or similar option-like instruments.</ecd:AwardTmgHowMnpiCnsdrdTextBlock>
    <ecd:MnpiDiscTimedForCompValFlag contextRef="c0" id="ixv-4121">false</ecd:MnpiDiscTimedForCompValFlag>
    <ecd:AwardTmgMnpiCnsdrdFlag contextRef="c0" id="ixv-4122">true</ecd:AwardTmgMnpiCnsdrdFlag>
    <ecd:AwardTmgMethodTextBlock contextRef="c0" id="ixv-4123">we
have generally granted such awards once a year to directors and executive officers, and equity awards may be granted at other times during
the year to newly hired or promoted employees, and in other special circumstances.</ecd:AwardTmgMethodTextBlock>
    <ecd:PvpTableTextBlock contextRef="c0" id="ixv-2811">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Pay
Versus Performance Table&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(in
thousands)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Included
in the table below is the annual compensation paid to our executives and our financial performance for each of the three previous years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Summary&lt;br/&gt; Compensation &lt;br/&gt;
Table &lt;br/&gt;
Total for &lt;br/&gt;
PEO(1)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Compensation &lt;br/&gt;
Actually &lt;br/&gt;
Paid to &lt;br/&gt;
PEO(3)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Average &lt;br/&gt;
Summary &lt;br/&gt;
Compensation &lt;br/&gt;
Table &lt;br/&gt;
Total for &lt;br/&gt;
Non-PEO &lt;br/&gt;
NEOs &lt;br/&gt;
Officer(2)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Average &lt;br/&gt;
Compensation &lt;br/&gt;
Actually &lt;br/&gt;
Paid to &lt;br/&gt;
Non-PEO &lt;br/&gt;
NEOs(3)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Value of &lt;br/&gt;
Initial &lt;br/&gt;
Fixed $100 &lt;br/&gt;
Investment &lt;br/&gt;
Based On: &lt;br/&gt;
Total &lt;br/&gt;
Shareholder &lt;br/&gt;
Return(4)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Net Income &lt;br/&gt;
(Loss)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; text-align: center"&gt;(a)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(b)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(c)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(d)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(e)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(f)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(g)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 28%; text-align: center; padding-left: 0.25pt"&gt;2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;568&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(203&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;259&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;78&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;70&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(7,121&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: center; padding-left: 0.25pt"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,821&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,699&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;717&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;979&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;118&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(13,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: center; padding-left: 0.25pt"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,006&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,453&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;320&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;103&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,927&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
fiscal years 2025, 2024, and 2023, this is the total compensation, as disclosed in the Summary Compensation Table above, for Mr. Ram
Mukunda, our Principal Executive Officer (&#x201c;PEO&#x201d;).&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
fiscal years 2025, 2024, and 2023, this is the total compensation, as disclosed in the Summary Compensation Table above, for Ms. Claudia
Grimaldi, our non-PEO NEO.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Compensation
Actually Paid is the Summary Compensation Table total for the PEO (column (b) above) and Summary Compensation Table total for the Non-PEO
(column (d) above), as applicable, with the adjustments pursuant to Item 402(v)(2)(iii)(C) of Regulations S-K.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The&#160;Total
Shareholder Return reflected in this column for each applicable fiscal year is calculated based on a fixed investment of $100 through
the end of the applicable fiscal year on the same cumulative basis.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;FYE 2025&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;FYE 2024&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;FYE 2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;FYE 2025&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;FYE 2024&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;FYE 2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1pt solid; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;PEO&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;PEO&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;PEO&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Non-PEO&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Non-PEO&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Non-PEO&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; width: 28%; font-weight: bold; text-align: left; padding-left: 0.125in"&gt;SCT Total Compensation&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;568&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,821&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,006&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;259&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;717&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;320&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"&gt;Subtract: Grant date fair value of equity awards granted during the covered year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,066&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(301&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(370&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(75&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"&gt;Add: Fair value as of the end of the covered fiscal year of all awards granted during the covered fiscal year that were outstanding and unvested as of the end of the fiscal covered year;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,517&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;159&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;535&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"&gt;Add: Change in fair value from the end of the prior fiscal year to the end of the covered fiscal year for awards granted in any prior fiscal year that were outstanding and unvested as of the end of the covered fiscal year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(663&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;158&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,804&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(148&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(129&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"&gt;Add: Fair value as of the vesting date of awards that were granted and vested in the same year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;234&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;79&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"&gt;Add: Change in fair value from the end of the prior fiscal year to the vesting date of awards granted in any prior fiscal year that vested in the covered fiscal year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(108&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(592&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(33&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(72&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"&gt;Subtract: Fair value at the end of the prior fiscal year of awards granted in any prior fiscal year that failed to vest (forfeited) in the covered fiscal year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-indent: -0.125in; text-align: left; padding-bottom: 1pt; padding-left: 0.125in"&gt;Add: Dollar amount of dividends or other earnings paid on equity awards in the covered fiscal year prior to the vesting date that are not included in total compensation for the covered fiscal year&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; font-weight: bold; text-align: left; padding-left: 0.125in"&gt;Compensation Actually Paid&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(203&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;2,699&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(1,453&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;78&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;979&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;103&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ecd:PvpTableTextBlock>
    <ecd:PeoTotalCompAmt contextRef="c0" decimals="-3" id="ixv-4124" unitRef="usd">568000</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt contextRef="c0" decimals="-3" id="ixv-4125" unitRef="usd">-203000</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt contextRef="c0" decimals="-3" id="ixv-4126" unitRef="usd">259000</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt contextRef="c0" decimals="-3" id="ixv-4127" unitRef="usd">78000</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt contextRef="c0" decimals="-3" id="ixv-4128" unitRef="usd">70000</ecd:TotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-4129" unitRef="usd">-7121000</us-gaap:NetIncomeLoss>
    <ecd:PeoTotalCompAmt contextRef="c1" decimals="-3" id="ixv-4130" unitRef="usd">1821000</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt contextRef="c1" decimals="-3" id="ixv-4131" unitRef="usd">2699000</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt contextRef="c1" decimals="-3" id="ixv-4132" unitRef="usd">717000</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt contextRef="c1" decimals="-3" id="ixv-4133" unitRef="usd">979000</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt contextRef="c1" decimals="-3" id="ixv-4134" unitRef="usd">118000</ecd:TotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss contextRef="c1" decimals="-3" id="ixv-4135" unitRef="usd">-13000000</us-gaap:NetIncomeLoss>
    <ecd:PeoTotalCompAmt contextRef="c2" decimals="-3" id="ixv-4136" unitRef="usd">1006000</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt contextRef="c2" decimals="-3" id="ixv-4137" unitRef="usd">-1453000</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt contextRef="c2" decimals="-3" id="ixv-4138" unitRef="usd">320000</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt contextRef="c2" decimals="-3" id="ixv-4139" unitRef="usd">103000</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt contextRef="c2" decimals="-3" id="ixv-4140" unitRef="usd">33000</ecd:TotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss contextRef="c2" decimals="-3" id="ixv-4141" unitRef="usd">-11927000</us-gaap:NetIncomeLoss>
    <ecd:NamedExecutiveOfficersFnTextBlock contextRef="c0" id="ixv-2973">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
fiscal years 2025, 2024, and 2023, this is the total compensation, as disclosed in the Summary Compensation Table above, for Mr. Ram
Mukunda, our Principal Executive Officer (&#x201c;PEO&#x201d;).&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
fiscal years 2025, 2024, and 2023, this is the total compensation, as disclosed in the Summary Compensation Table above, for Ms. Claudia
Grimaldi, our non-PEO NEO.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</ecd:NamedExecutiveOfficersFnTextBlock>
    <ecd:PeoName contextRef="c2" id="ixv-4142">Mr. Ram Mukunda</ecd:PeoName>
    <ecd:PeoName contextRef="c1" id="ixv-4143">Mr. Ram Mukunda</ecd:PeoName>
    <ecd:PeoName contextRef="c0" id="ixv-4144">Mr. Ram Mukunda</ecd:PeoName>
    <ecd:Additional402vDisclosureTextBlock contextRef="c0" id="ixv-2997">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Compensation
Actually Paid is the Summary Compensation Table total for the PEO (column (b) above) and Summary Compensation Table total for the Non-PEO
(column (d) above), as applicable, with the adjustments pursuant to Item 402(v)(2)(iii)(C) of Regulations S-K.&lt;/span&gt;</ecd:Additional402vDisclosureTextBlock>
    <ecd:AdjToPeoCompFnTextBlock contextRef="c0" id="ixv-3028">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;FYE 2025&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;FYE 2024&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;FYE 2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;FYE 2025&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;FYE 2024&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;FYE 2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1pt solid; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;PEO&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;PEO&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;PEO&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Non-PEO&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Non-PEO&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Non-PEO&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; width: 28%; font-weight: bold; text-align: left; padding-left: 0.125in"&gt;SCT Total Compensation&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;568&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,821&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,006&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;259&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;717&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;320&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"&gt;Subtract: Grant date fair value of equity awards granted during the covered year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,066&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(301&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(370&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(75&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"&gt;Add: Fair value as of the end of the covered fiscal year of all awards granted during the covered fiscal year that were outstanding and unvested as of the end of the fiscal covered year;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,517&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;159&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;535&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"&gt;Add: Change in fair value from the end of the prior fiscal year to the end of the covered fiscal year for awards granted in any prior fiscal year that were outstanding and unvested as of the end of the covered fiscal year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(663&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;158&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,804&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(148&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(129&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"&gt;Add: Fair value as of the vesting date of awards that were granted and vested in the same year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;234&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;79&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"&gt;Add: Change in fair value from the end of the prior fiscal year to the vesting date of awards granted in any prior fiscal year that vested in the covered fiscal year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(108&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(592&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(33&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(72&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"&gt;Subtract: Fair value at the end of the prior fiscal year of awards granted in any prior fiscal year that failed to vest (forfeited) in the covered fiscal year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-indent: -0.125in; text-align: left; padding-bottom: 1pt; padding-left: 0.125in"&gt;Add: Dollar amount of dividends or other earnings paid on equity awards in the covered fiscal year prior to the vesting date that are not included in total compensation for the covered fiscal year&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; font-weight: bold; text-align: left; padding-left: 0.125in"&gt;Compensation Actually Paid&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(203&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;2,699&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(1,453&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;78&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;979&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;103&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ecd:AdjToPeoCompFnTextBlock>
    <ecd:AdjToNonPeoNeoCompFnTextBlock contextRef="c0" id="ixv-3029">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;FYE 2025&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;FYE 2024&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;FYE 2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;FYE 2025&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;FYE 2024&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;FYE 2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1pt solid; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;PEO&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;PEO&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;PEO&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Non-PEO&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Non-PEO&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Non-PEO&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; width: 28%; font-weight: bold; text-align: left; padding-left: 0.125in"&gt;SCT Total Compensation&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;568&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,821&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,006&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;259&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;717&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;320&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"&gt;Subtract: Grant date fair value of equity awards granted during the covered year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,066&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(301&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(370&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(75&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"&gt;Add: Fair value as of the end of the covered fiscal year of all awards granted during the covered fiscal year that were outstanding and unvested as of the end of the fiscal covered year;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,517&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;159&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;535&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"&gt;Add: Change in fair value from the end of the prior fiscal year to the end of the covered fiscal year for awards granted in any prior fiscal year that were outstanding and unvested as of the end of the covered fiscal year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(663&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;158&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,804&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(148&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(129&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"&gt;Add: Fair value as of the vesting date of awards that were granted and vested in the same year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;234&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;79&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"&gt;Add: Change in fair value from the end of the prior fiscal year to the vesting date of awards granted in any prior fiscal year that vested in the covered fiscal year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(108&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(592&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(33&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(72&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"&gt;Subtract: Fair value at the end of the prior fiscal year of awards granted in any prior fiscal year that failed to vest (forfeited) in the covered fiscal year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-indent: -0.125in; text-align: left; padding-bottom: 1pt; padding-left: 0.125in"&gt;Add: Dollar amount of dividends or other earnings paid on equity awards in the covered fiscal year prior to the vesting date that are not included in total compensation for the covered fiscal year&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; font-weight: bold; text-align: left; padding-left: 0.125in"&gt;Compensation Actually Paid&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(203&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;2,699&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(1,453&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;78&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;979&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;103&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</ecd:AdjToNonPeoNeoCompFnTextBlock>
    <ecd:PeoTotalCompAmt contextRef="c0" decimals="-3" id="ixv-4145" unitRef="usd">568000</ecd:PeoTotalCompAmt>
    <ecd:PeoTotalCompAmt contextRef="c1" decimals="-3" id="ixv-4146" unitRef="usd">1821000</ecd:PeoTotalCompAmt>
    <ecd:PeoTotalCompAmt contextRef="c2" decimals="-3" id="ixv-4147" unitRef="usd">1006000</ecd:PeoTotalCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt contextRef="c0" decimals="-3" id="ixv-4148" unitRef="usd">259000</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt contextRef="c1" decimals="-3" id="ixv-4149" unitRef="usd">717000</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt contextRef="c2" decimals="-3" id="ixv-4150" unitRef="usd">320000</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:AdjToCompAmt contextRef="c3" decimals="-3" id="ixv-4151" unitRef="usd">0</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c4" decimals="-3" id="ixv-4152" unitRef="usd">-1066000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c5" decimals="-3" id="ixv-4153" unitRef="usd">-301000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c6" decimals="-3" id="ixv-4154" unitRef="usd">0</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c7" decimals="-3" id="ixv-4155" unitRef="usd">-370000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c8" decimals="-3" id="ixv-4156" unitRef="usd">-75000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c9" decimals="-3" id="ixv-4157" unitRef="usd">0</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c10" decimals="-3" id="ixv-4158" unitRef="usd">1517000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c11" decimals="-3" id="ixv-4159" unitRef="usd">159000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c12" decimals="-3" id="ixv-4160" unitRef="usd">0</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c13" decimals="-3" id="ixv-4161" unitRef="usd">535000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c14" decimals="-3" id="ixv-4162" unitRef="usd">40000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c15" decimals="-3" id="ixv-4163" unitRef="usd">-663000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c16" decimals="-3" id="ixv-4164" unitRef="usd">158000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c17" decimals="-3" id="ixv-4165" unitRef="usd">-1804000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c18" decimals="-3" id="ixv-4166" unitRef="usd">-148000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c19" decimals="-3" id="ixv-4167" unitRef="usd">10000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c20" decimals="-3" id="ixv-4168" unitRef="usd">-129000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c21" decimals="-3" id="ixv-4169" unitRef="usd">0</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c22" decimals="-3" id="ixv-4170" unitRef="usd">234000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c23" decimals="-3" id="ixv-4171" unitRef="usd">79000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c24" decimals="-3" id="ixv-4172" unitRef="usd">0</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c25" decimals="-3" id="ixv-4173" unitRef="usd">78000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c26" decimals="-3" id="ixv-4174" unitRef="usd">20000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c27" decimals="-3" id="ixv-4175" unitRef="usd">-108000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c28" decimals="-3" id="ixv-4176" unitRef="usd">34000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c29" decimals="-3" id="ixv-4177" unitRef="usd">-592000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c30" decimals="-3" id="ixv-4178" unitRef="usd">-33000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c31" decimals="-3" id="ixv-4179" unitRef="usd">8000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c32" decimals="-3" id="ixv-4180" unitRef="usd">-72000</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c33" decimals="-3" id="ixv-4181" unitRef="usd">0</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c34" decimals="-3" id="ixv-4182" unitRef="usd">0</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c35" decimals="-3" id="ixv-4183" unitRef="usd">0</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c36" decimals="-3" id="ixv-4184" unitRef="usd">0</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c37" decimals="-3" id="ixv-4185" unitRef="usd">0</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c38" decimals="-3" id="ixv-4186" unitRef="usd">0</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c39" decimals="-3" id="ixv-4187" unitRef="usd">0</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c40" decimals="-3" id="ixv-4188" unitRef="usd">0</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c41" decimals="-3" id="ixv-4189" unitRef="usd">0</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c42" decimals="-3" id="ixv-4190" unitRef="usd">0</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c43" decimals="-3" id="ixv-4191" unitRef="usd">0</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt contextRef="c44" decimals="-3" id="ixv-4192" unitRef="usd">0</ecd:AdjToCompAmt>
    <ecd:PeoActuallyPaidCompAmt contextRef="c0" decimals="-3" id="ixv-4193" unitRef="usd">-203000</ecd:PeoActuallyPaidCompAmt>
    <ecd:PeoActuallyPaidCompAmt contextRef="c1" decimals="-3" id="ixv-4194" unitRef="usd">2699000</ecd:PeoActuallyPaidCompAmt>
    <ecd:PeoActuallyPaidCompAmt contextRef="c2" decimals="-3" id="ixv-4195" unitRef="usd">-1453000</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt contextRef="c0" decimals="-3" id="ixv-4196" unitRef="usd">78000</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt contextRef="c1" decimals="-3" id="ixv-4197" unitRef="usd">979000</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt contextRef="c2" decimals="-3" id="ixv-4198" unitRef="usd">103000</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:CompActuallyPaidVsOtherMeasureTextBlock contextRef="c45" id="ixv-3323">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Relationship
Between Compensation Actually Paid and Operational Milestones&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company does not look to net income (loss) as a performance measure for its executive compensation program and instead looks at operational
metrics, such as drug development milestones, pipeline progress, R&amp;amp;D spend, regulatory compliance, intellectual property, partnerships,
collaborations, and general financial health of the Company. The compensation actually paid for both our PEO and non-PEO NEO decreased
between the 2024 fiscal year and Fiscal 2025. This is primarily because the compensation is structured with stock, and the stock did
not perform well despite meeting operational milestones.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
compensation actually paid to our named executive officers from Fiscal 2025 versus the 2024 fiscal year generally reflects cash bonuses
and stock awards, some of which vest based on milestones and others based on time. In addition, the Company decreased operating loss
reflecting a diligent commitment to the financial health of the Company.&lt;/span&gt;&lt;/p&gt;</ecd:CompActuallyPaidVsOtherMeasureTextBlock>
    <ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock contextRef="c0" id="ixv-3339">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Relationship
Between Compensation Actually Paid and Company Total Shareholder Return&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Part
of the overall compensation is the stock price. In fiscal years 2025 and 2024, the metrics set by the Compensation Committee and the
Board with respect to stock price were not met. The PEO and non-PEO were therefore compensated based on shareholder return or value of
stock during the fiscal year in each of the 2025 and 2024 fiscal years in the form of stock awards based on market-based milestones.
These stock milestones are described under the Narrative to Summary Compensation Table section of this Proxy Statement.&lt;/span&gt;&lt;/p&gt;</ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock>
    <dei:DocumentType contextRef="c0" id="hidden-fact-0">PRE 14A</dei:DocumentType>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-4202">0001326205</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c0" id="ixv-4203">false</dei:AmendmentFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
